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SUMMARY 
Poly(ADP-ribose) polymerase 1 (PARP1) cleavage is the hallmark of apoptosis. 
Yet PARP1 cleavage is not necessary for apoptosis, suggesting that it has another 
physiological role. Here we show that caspase 7 is a target of the NALP3 
inflammasome-activated caspase 1 in LPS stimulated macrophages. Active 
caspase 7 in turn translocates to the nucleus and cleaves PARP1 to regulate NF-
κB target gene expression. Mutation of the aspartic acid residue at the PARP1 
cleavage site (D214) abolishes caspase 7-mediated PARP1 cleavage and release of 
PARP1 from chromatin, thus maintaining chromatin compaction and 
restraining gene induction necessary for the host response. These findings 
propose a non-apoptotic regulatory role for caspase 7 in PARP1-dependent 
transcription and provide novel mechanistic insights into how the 
inflammasomes can relay inflammatory signals to transcription. 
 
Keywords: PARP-1; caspase 7; inflammasome; transcription; chromatin; NF-κB 
Short title: Inflammasome-regulated gene expression 
 
HIGHLIGHTS 
• Caspase 7 mediates non-apoptotic PARP1 cleavage upon inflammatory 
stimulus  
• NALP3 inflammasome regulates transcription via caspase 1 and 7 
• PARP1 cleavage at D214 enhances NF-κB target gene expression 
• PARP1 cleavage increases chromatin accessibility 
 
GRAPHICAL ABSTRACT 
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INTRODUCTION 
 
Induction of Nuclear factor kappaB (NF-κB) signal transduction pathways occurs in 
response to a wide range of stimuli and results in nuclear accumulation of NF-κB 
transcription factors and expression of a large number of target genes (Mankan et al., 
2009). Appropriate regulation of NF-κB is critical for the function and survival of the 
cell and aberrant NF-κB activity has been implicated in the pathogenesis of several 
diseases (Ghosh and Hayden, 2008). There is an increased understanding of the 
importance of nuclear events in regulating NF-κB's activities as a transcription factor, 
including reversible post-translational modification of the transcription factor itself 
(e.g. acetylation), recruitment of cofactors (e.g. CBP/p300) or the role of chromatin 
structure (Lomvardas and Thanos, 2002; Natoli, 2006; Ramirez-Carrozzi et al., 2009). 
 Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear chromatin-associated 
multifunctional enzyme found in most eukaryotes apart from yeast (Hassa et al., 
2006). PARP1 is able to catalyze polymerization of ADP-ribose units from donor 
NAD+ molecules (Hassa et al., 2006; Kim et al., 2005). The enzyme has only low 
basal activity but is activated by damaged DNA in vivo or by stem/loop boundaries of 
cruciform hairpins of undamaged genomic DNA (Woodhouse and Dianov, 2008). The 
targets of PARP1’s enzymatic activity include a variety of nuclear proteins, including 
PARP1 itself and histones (Quénet et al., 2009). Recent studies have suggested a role 
for PARP1 in the regulation of chromatin structure and transcription, including NF-
κB-dependent gene expression (Hassa et al., 2006; Hassa and Hottiger, 1999; Kraus, 
2008). During apoptosis, PARP1 is cleaved by caspases, a hallmark of cell death 
(Nicholson et al., 1995; Tewari et al., 1995). Caspase 3 and 7 are responsible in vivo 
to process PARP1 to its apoptotic 24- and 89-kDa fragments (Nicholson and 
Thornberry, 1997; Salvesen and Dixit, 1997). The p24 fragment, which contains a 
part of the DNA binding domain (DBD) is thought to recognize altered structures in 
DNA rather than particular sequences and has also been reported to be involved in 
protein–protein interactions (Hassa et al., 2006; Pion et al., 2005). Without the 24kDa 
amino-terminal domain, the 89kDa fragment cannot be activated by DNA (Altmeyer 
et al., 2009). 
 Caspases belong to a family of highly conserved cysteine-dependent aspartate-
specific proteases (Alnemri et al., 1996). The human caspase gene family consists of 
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12 mammalian members that are grouped into two major sub-families, namely 
inflammatory and apoptotic caspases (Chowdhury et al., 2008). Caspase 1 is the 
prototypical member of the inflammatory caspases and following its recruitment and 
activation within large cytoplasmic complexes, called inflammasomes, mediates the 
maturation of inflammatory cytokines like pro-IL-1β and pro-IL-18 (Ghayur et al., 
1997; Martinon et al., 2004; Thornberry et al., 1992). Genetic studies in mice suggest 
at least four inflammasomes, with distinct components and activating stimuli. The 
identity of the inflammasome depends on the nature of the nucleotide binding and 
oligomerization domain (NOD)-like receptor (NLR) members. The interaction 
between NLR proteins and inflammatory caspases is mediated by the bipartite adaptor 
protein ASC. Deletion of ASC abolishes inflammasome activation in response to a 
wide range of triggers (Mariathasan et al., 2004). Inflammasome formation can be 
induced by a variety of PAMPs (pathogen-associated molecular patterns). For 
example, NALP3 inflammasome formation can be triggered by LPS, bacterial toxins, 
double stranded RNA or whole pathogens like Candida albicans, whereas IPAF 
inflammasome is activated by gram-negative bacteria like Salmonella typhimurium 
(Schroder and Tschopp, 2010). The activation mechanisms for NALP1b and AIM2 
inflammasomes are less clear but Bacillus anthracis lethal toxin or vaccinia virus 
have been reported to require the NALP1b and AIM2 inflammasome for caspase 1 
processing, respectively (Fink et al., 2008; Hornung et al., 2009). 
 On the other hand, caspase 3 and 7 were identified as key mediators of 
apoptosis (Nicholson et al., 1995; Tewari et al., 1995). Activation of caspases requires 
proteolytical removal of the linker region between large and small catalytic subunits 
(Boatright et al., 2003). In turn, active caspase 3 and 7 cleave a large set of substrates 
that ultimately results in apoptosis. (Kuida et al., 1996). Whereas caspase 3 and 
caspase 7 knock-out mice show no phenotypic abnormalities, caspase3/7 double 
knock-out mice suffer from early perinatal lethality, indicating the redundant roles 
caspase 3 and 7 play during embryonic development (Lakhani et al., 2006). However, 
accumulating evidence suggests also non-redundant roles and non-apoptotic functions 
for caspase 3 and caspase 7 in different cellular processes such as cell proliferation, 
cell-cycle regulation, and cell differentiation and inflammation (Algeciras-Schimnich 
et al., 2002; Denis et al., 1998; Lamkanfi et al., 2008). 
 Interestingly, PARP1 knock-in mice (D214N), which harbor a mutated 
caspase cleavage site of PARP1, DEVD214, develop normally, indicating that cleavage 
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of PARP1 is not required during apoptosis (Pétrilli et al., 2004). This observation 
raises a fundamental question why there should be such an elaborate mechanism for 
selective degradation of a subset of cellular proteins, when eventually all the cellular 
components need to be destroyed An obvious answer would be that the targeted 
cleavage is important for regulatory functions other than apoptosis. Intriguingly, 
PARP1 knock-in mice (D214N) are highly resistant to endotoxic shock and to 
intestinal and renal ischemia-reperfusions (Pétrilli et al., 2004). Target tissues and 
cells show reduced inflammatory responses due to the compromised production of 
specific inflammatory mediators, suggesting that cleavage of PARP1 is functionally 
relevant for inflammation dependent gene expression.  
 Here we have examined the role of PARP1 cleavage at the molecular level 
under inflammatory conditions. We found that PARP1 is cleaved at D214 by caspase 
7 after stimulation of macrophages with LPS. LPS activated caspase 7 is a target of 
the NALP3 inflammasome and its absence compromised NF-κB target gene 
induction. LPS activated, proteolytic PARP1 cleavage releases PARP1 from 
chromatin, reduces chromatin compaction and enhances NF-κB-dependent gene 
expression suggesting a regulatory non-apoptotic role of caspase 7 and linking 
caspase 7 to inflammation and transcription. 
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RESULTS 
 
Induction of a Subset of NF-κB Target Genes is Compromised in Peritoneal 
Macrophages Isolated from D214N PARP1 Mice. 
We first asked whether PARP1 cleavage is induced with an inflammatory stimulus 
like LPS. Peritoneal macrophages from C57Bl/6 mice expressing either WT or non-
cleavable D214N PARP1 were isolated, stimulated with LPS and subjected to western 
blotting. With an antibody recognizing cleaved C-terminal PARP1 fragment, we 
observed that PARP1 cleavage (p89) was rapid and detected as early as 1 hour (Fig 
1A). To investigate a potential regulatory role of PARP1 cleavage in NF-κB 
dependent gene expression, intraperitoneal macrophages (IP cells) were stimulated 
with LPS and pro-inflammatory gene expression was analysed. Real-time RT-PCR 
revealed that LPS dependent induction of CSF2, IL-6 and LIF was dependent on 
PARP1 cleavage in these cells, but not the one of IP-10 (Fig. 1B). To investigate if 
the reduced gene induction in D214N PARP1 cells was due to inefficient p65-PARP1 
complex formation or hampered recruitment of p65 to DNA, immunoprecipitation 
and ChIP experiments were performed in IP cells, respectively. LPS induced complex 
formation between p65 and PARP1 was not affected by the D214N mutation (Fig. 
S1A). Likewise, p65 recruitment to target promoters such as CSF2, IL-6 and IP-10 
occurred as soon as 30 minutes and was comparable in WT and D214N IP cells (Fig. 
1C). These results suggest that PARP1 cleavage might regulate the induction of a 
subset of NF-κB dependent genes and that the moderate gene induction in D214N IP 
cells is not due to reduced complex formation with p65 nor deficient NF-κB 
signaling. 
 
LPS Induced PARP1 Cleavage Regulates the Expression of IL-6 in THP1 Cells. 
Next, we tested whether the above-mentioned observations could be extended to 
human THP1 monocyte/macrophage like cells. THP1 monocyte-like cells can be 
differentiated to macrophage-like cells by treatment with PMA. We first tested 
whether LPS would induce PARP1 cleavage in PMA primed human THP1 cells. 
Indeed, after stimulation of THP1 cells with LPS for different time periods ranging 
from 2 to 6 hours, PARP1 cleavage was detected by western blot using an antibody 
detecting the C-terminal large PARP1 fragment (p89) resulting from cleavage at 
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D214 (Fig. 2A). Similar results were obtained with unprimed THP1 cells (Fig. S1B). 
Since PARP1 cleavage is a hallmark of apoptosis, we next investigated whether LPS 
treatment of THP1 cells induces cell death under the tested conditions. Stimulated 
THP1 cells were stained with ethidium homodimer and calcein for dying and viable 
cells, respectively. While treatment of cells with camptothecin induced significant 
increase in the amount of dead cells, LPS stimulation did not induce any detectable 
increase in cell death for the indicated time period (Fig. 2B). 
 To further investigate the physiological relevance of LPS-induced PARP1 
cleavage in these cells, THP1 cells were transduced with a lentivirus containing 
shRNA against PARP1 or a scrambled control RNA (Fig. 2C). Clones efficiently 
depleted of PARP1 were subsequently complemented by retroviral transduction with 
an empty vector (PRRL), the myc-tagged full-length WT or the D214N non-cleavable 
mutant PARP1 (Fig. 2D). Complemented THP1 cells confirmed that PARP1 was not 
cleaved when mutated (D214N, Fig. S1C). Stimulation of these cells for 1 hour with 
LPS, and subsequent expression analysis of pro-inflammatory genes by real-time RT-
PCR revealed that IP-10 and COX-2 expression increased to the same extent in WT 
and D214N PARP1 THP1 cells (Fig. 2E). Interestingly, the gene induction of IL-6 
was significantly reduced in cells complemented with non-cleavable PARP1, 
suggesting that PARP1 cleavage is also important for the transcriptional activation of 
a subset of NF-κB target genes in human THP1 cells.  
  
Caspase 7 Cleaves PARP1 at D214N in vitro and Enhances NF-κB Dependent 
Gene Induction in vivo. 
PARP1 cleavage at D214 is mediated by caspases (Lazebnik et al., 1994). To 
investigate whether caspases are also responsible for the LPS induced PARP1 
cleavage, peritoneal macrophages were stimulated with LPS for different times in the 
absence or presence of pan caspase inhibitor Z-VAD-fmk. Western blot analysis 
showed that LPS dependent PARP1 cleavage was abrogated in the presence of Z-
VAD-fmk (Fig. 3A). This effect was specific to Z-VAD-fmk and was not observed 
with another inhibitor, cycloheximide (CHX) which inhibits protein synthesis (Fig. 
S1D). These results suggest that caspases are responsible for LPS induced PARP1 
cleavage, yet which caspase cleaves PARP1 upon LPS stimulation is unknown. We 
thus examined in vitro the caspases that efficiently cleave PARP1 at D214. WT and 
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D214N mutant PARP1 were both in vitro translated and subsequently incubated with 
different purified active human caspases (caspase 1-10). Caspases 3 and 7 were found 
to cleave PARP1 most efficiently, while caspases 1, 8 as well as 6 and 10 also 
processed PARP1 under the tested conditions, although to a different extent (Fig. 3B, 
upper blot). In most of the observed cases, cleavage took place at D214, since the 
corresponding D214N PARP1 mutant was not cleaved under the tested conditions. To 
exclude that other proteases from the reticulo-lysate were responsible for the observed 
cleavage, experiments were repeated with recombinant wild type and D214N PARP1 
mutant proteins expressed in the baculo system. Western blot analysis with an 
antibody directed against the catalytic domain of PARP1 confirmed that PARP1 is 
predominantly cleaved at D214 by caspase 3 and 7 and to a lesser extent by caspases 
6, 8 and 10 (Fig. 3B, lower blot). 
 To investigate whether caspase 7 or its close relative caspase 3 have a 
functional role in LPS-dependent NF-κB gene induction, we next transiently 
transfected IP cells with siRNA oligos targeting caspase 3 or 7 and stimulated them 
with LPS for one hour. Real-time RT-PCR analysis revealed that induction of a subset 
of NF-κB target genes was reduced in cells transfected with caspase 7 siRNA (Fig. 
3C). In contrast, caspase 3 knock-down had either beneficial or no effect on NF-κB 
gene activation implicating that caspase 3 and 7 have distinct functions in mediating 
pro-inflammatory gene expression. Similar results were obtained in PMA primed 
THP1 cells (Fig. S2A). Interestingly, genes that showed reduced induction upon 
caspase 7 knock-down overlapped with the genes that showed dependency on PARP1 
cleavage, suggesting that the observed effect of caspase 7 on NF-κB might be 
mediated by PARP1 cleavage. To confirm that the LPS dependent role of caspase 7 
on NF-κB is linked to PARP1 cleavage, THP1 cells expressing WT or D214N PARP1 
(Fig. 2D) were PMA primed, transiently transfected with mock or caspase 7 siRNA 
oligos and stimulated one hour with LPS. Indeed, real-time RT-PCR analysis revealed 
that caspase 7 knock-down led to 50% reduction in IL-6 gene induction in WT 
PARP1 expressing THP1 cells, whereas no significant effect was observed upon 
caspase 7 knock-down in D214N PARP1 expressing THP1 cells (Fig. 3D and S2B). 
To investigate whether caspase 7 would translocate to the nucleus upon LPS induction 
where PARP1 is localized, THP1 monocytes were stimulated with LPS for 1.5 or 3.5 
hours and cytoplasmic and nuclear fractions were prepared. Western blot analysis 
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with an antibody that detects only the activated caspase 7 resulting from cleavage at 
Asp198 (p19) revealed that active caspase 7 was absent from the nucleus in the 
unstimulated state but translocated to nucleus as soon as 1.5 hours after stimulation. 
Full-length (F.L) caspase 7 levels, on the other hand, did not change upon LPS 
stimulation and it was mainly localized to cytoplasm, suggesting that the cleaved 
caspase 7 is a very minor portion of the total caspase 7 pool. In accordance with the 
above-proposed role for caspase 7 in PARP1 cleavage, kinetics of PARP1 cleavage 
paralleled active caspase appearance in the nucleus. PARP1 and tubulin blots showed 
the pureness of the nuclear and cytoplasmic fractions, respectively. Taken together, 
we conclude that caspase 7 has a pro-inflammatory role in NF-κB mediated gene 
induction and this effect is mainly mediated by PARP1 cleavage.  
 
Caspase 7 Is a Target of NALP3 Inflammasome. 
 Next, we investigated the molecular pathways that lead to caspase 7 activation 
under inflammatory conditions. Pro-inflammatory effects seen for caspase 7 
encouraged us to test the link between PARP1 cleavage, inflammatory caspase 1 and 
caspase 7. Peritoneal macrophages from WT, caspase 1 -/- and caspase 7 -/- mice 
were stimulated with LPS for different times ranging from 1 hour to 16 hours and 
PARP1 cleavage was monitored by western blotting. In WT cells, PARP1 cleavage 
was visible as early as one hour after stimulation but not in caspase 7 -/- cells, 
confirming the above proposed role for caspase 7 in cleaving PARP1 upon LPS 
stimulation in vivo (Fig. 4A). Interestingly, also in caspase 1 -/- cells no PARP1 
cleavage was detected. Furthermore, activation of caspase 1 and caspase 7 upon LPS 
stimulation correlated with PARP1 cleavage, suggesting an interplay between caspase 
1, caspase 7 and PARP1 cleavage under inflammatory conditions. In caspase 1 -/- 
cells, caspase 7 activation was absent whereas in caspase 7 -/- cells, LPS dependent 
caspase 1 activation was not effected, providing evidence that caspase 1 is upstream 
of caspase 7 activation, not vice versa. Furthermore, caspase 7 was not required for 
the inflammasome formation that was activated upon various other stimuli (Fig. S3A 
and S3B). Caspase 1 is the best characterized inflammatory caspase and its catalytic 
activity is tightly regulated by signal dependent autoactivation of inflammasomes 
(Martinon et al., 2002). NALP3 inflammasome can be activated by exposure to 
bacterial products like LPS (Mariathasan et al., 2004). We thus tested whether LPS 
dependent caspase 7 activation requires the NALP3 inflammasome components. LPS 
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dependent caspase 1 activation but also caspase 7 activation was abolished in bone 
marrow derived macrophages (BMDMs) lacking NALP3 (Fig. 4B). Similarly, in 
intraperitoneal macrophages lacking the essential inflammasome adaptor ASC, LPS 
dependent caspase 1 activation, caspase 7 activation and PARP1 cleavage was 
abolished indicating that LPS dependent caspase 7 activation is mediated by caspase 1 
containing NALP3 inflammasome (Fig. 4B and 4C). To investigate whether the 
signaling pathway leading to caspase 7 activation was functional in D214N PARP1 
cells, intraperitoneal macrophages from WT and D214N PARP1 mice were 
stimulated with LPS for different times and total proteins were analyzed by western 
blot. Western blot analysis revealed that LPS induction led to comparable caspase 1 
and 7 activation in both of the cell lines (Fig. 4D). 
 
PARP1 Dissociates from IL-6 Transcription Start Site upon LPS Induction. 
PARP1 cleavage by caspase 7 generates 24- and 89kDa fragments of which the 
smaller one contains a part of PARP1’s DBD (Altmeyer et al., 2009; Hassa and 
Hottiger, 2008). We recently reported that PARP1 is acetylated in a stimuli dependent 
manner and that this acetylation is reversible by type I HDACs (Hassa et al., 2005). 
To investigate whether HDACs are able to interact with the cleaved PARP1 fragments 
in vivo, we performed immunoprecipitation experiments with p24 and p89 together 
with HDAC1 and 2. HDAC1 and 2 interacted with full-length PARP1 and p24 but not 
with p89 in vivo (Fig. 5A and 5B). Since HDAC activities are described to condense 
chromatin structure and thereby inhibit transcription, we hypothesized that PARP1 
cleavage could be a means of removing the inhibitory HDACs from the chromatin 
upon LPS stimulation. ChIP experiments using anti-myc antibody to 
immunoprecipitate amino-terminally tagged PARP1 in THP1 cells (see Fig. 2D) 
revealed that p24 association was reduced at the transcriptional start site (TSS) of IL-6 
upon LPS stimulation in cells complemented with WT PARP1. In contrast, the myc-
tagged amino-terminal part of PARP1 was still detectable in cells complemented with 
non-cleavable PARP1 (D214N) (Fig. 5C). Interestingly, PARP1 seemed even to be 
enriched at the IL-6 TSS in these cells upon LPS stimulation. This was not observed 
for the TSS of H2B, which served as control gene. These results suggest that lack of 
PARP1 cleavage does not allow dissociation of full-length PARP1 from chromatin 
and this correlates with reduced gene induction upon LPS treatment. The observed 
dissociation of WT PARP1 rather depended on the cleavage at D214 than on the 
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ADP-ribosylation activity of PARP1, since both, WT and D214N PARP1 proteins 
were comparably enzymatically active (Fig. 5D). In addition, LPS treatment did not 
lead to any detectable poly-ADP-ribose formation as analyzed by 
immunofluorescence microscopy (data not shown). We earlier reported that full-
length PARP1 is required for pre-initiation complex (PIC) formation of NF-κB 
(Hassa and Hottiger, 1999). Therefore, we tested whether the cleaved PARP1 
fragments would still be able to interact with p65 and potentially contribute to NF-
κB-dependent gene expression. Interaction of recombinant PARP1 proteins with full-
length GST-p65 was analyzed by pull-down experiments. Both full-length proteins 
(WT and D214N) interacted with p65 to a comparable extent (Fig. 5E, left panel). 
However, the cleaved PARP1 p89 fragment did not bind p65 under the tested 
conditions. Similar experiments with PARP1 p24 suggested that also the smaller 
fragment of PARP1 is not able to interact with p65 (Fig. 5E, right panel). Together, 
both experiments revealed that while full-length PARP1 binds to p65, cleaved PARP1 
fragments do not interact with p65 implicating that once PARP1 is cleaved by caspase 
7, the cleaved PARP1 fragments most probably are not any longer required for p65 
dependent gene expression and thus not the cause for the compromised gene induction 
in D214N PARP1 cells.   
 
PARP1 Cleavage by LPS Enhances Chromatin Accessibility around the TSS. 
Next, we isolated BMDMs from WT or D214N PARP1 mice and analyzed pro-
inflammatory gene expression in these cell lines. In agreement with previous results, 
stimulation of these primary cells with LPS for one hour and subsequent real-time 
RT-PCR analysis revealed also in primary BMDMs a subset of LPS-induced NF-κB 
target genes to be dependent on PARP1 cleavage. While the induction of CSF2 and 
NOS-2 were strongly reduced in BMDM isolated from D214N PARP1 knock-in mice, 
the expression of IP-10 or MIP-2 was not affected (Fig. 6A).  
We sought to gain more mechanistic insights into LPS activated PARP1 
cleavage and enhancement of gene activation. PARP1 is reported to compact 
chromatin in vitro (Wacker et al., 2007) and we observed HDAC1and 2 to interact 
with PARP1 and p24 (Fig. 5A and 5B). Therefore, we asked whether cleavage of 
PARP1 and the release of these fragments from chromatin would lead to more 
accessible chromatin and enhanced transcription. To address this question, chromatin 
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accessibility assay was performed in primary BMDMs isolated from mice. Nuclei 
from unstimulated or one hour LPS stimulated cells were isolated and digested with 
MNase and subsequently analyzed by CHART-PCR. Chromatin at the TSS of NF-κB 
target genes like CSF2 or NOS-2 became more accessible upon LPS stimulation (Fig. 
6B, upper panel, grey bars), correlating with chromatin release of PARP1 and the 
increase in gene expression. This effect was much more pronounced around the TSS 
than 1kB upstream of this site. Interestingly, analysis of the corresponding site in cells 
isolated from D214N PARP1 mice revealed that the extent of chromatin 
decompaction was significantly reduced upon LPS stimulation (Fig. 6B, lower panel, 
grey bars), providing strong evidence that PARP1 cleavage and release are decreasing 
chromatin compaction at the TSS in vivo and thereby enhance gene activation. Similar 
results were obtained for the chromatin around CSF2 TSS in IP cells (Fig. S4). 
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DISCUSSION 
 
In this study we have characterized the activation of caspase 7 by NALP3 
inflammasome and determined its role in the activation of NF-κB-dependent gene 
expression through PARP1 cleavage. We provide evidence that the observed cleavage 
of PARP1 is not a consequence of induced apoptosis, but represents rather a novel 
non-apoptotic function of caspase 7. We show that activated caspase 7 cleaves 
PARP1 at the TSS of certain genes to release PARP1 from the chromatin and allow 
productive NF-κB dependent gene expression. Our conclusions are based on several 
observations: (i) on differential gene expression in mouse primary cells and in human 
THP1 cells genetically complemented with WT or non-cleavable D214N PARP1, (ii) 
on different mouse models lacking individual components of NALP3 inflammasome 
(iii) on ChIP experiments for PARP1, (iv) on differential chromatin accessibilities 
based on MNase experiments.  
 Caspase 7 knock-down in THP1 cells expressing uncleavable PARP1 did not 
affect the NF-κB response to LPS whereas THP1 cells expressing WT PARP1 did. 
Active caspase 7 also translocated to the nucleus upon LPS stimulation. This suggests 
that PARP1 is a main nuclear target of caspase 7 for the observed LPS induced 
transcriptional response. We can currently not exclude that active caspase 7 is 
cleaving additional proteins important for other cellular processes during LPS 
stimulation. Only a very small fraction of cellular caspase 7 was activated and 
translocated into the nucleus to cleave a very minor fraction of the cellular PARP1 
pool at the TSS (Fig. 4A, 4D and S1B). This points at a very tight regulation, which 
makes sense in terms of not initiating a detrimental response for the cell under 
inflammatory conditions. It might be achieved by LPS-induced activation of a very 
distinct cytoplasmic complex containing caspase 7 and/or the induction of a post-
translational modification, which would allow caspase 7 to translocate to the nucleus. 
Alternatively, the activity of caspase 7 might be regulated by xIAP, which is a natural 
and potent inhibitor of caspase 7 (Deveraux et al., 1997). 
A recent proteomic study revealed that caspase 7 (but not caspase 3) is a 
downstream target of caspase 1 which provides evidence for the existence of distinct 
activation mechanisms for caspase 3 and 7 in response to microbial stimuli and 
bacterial infection (Lamkanfi et al., 2008). Our results are in agreement with this 
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study. However, Lamkanfi et al. have used pure LPS and ATP to activate caspase 1 
whereas we used throughout our study crude LPS without ATP (Lamkanfi et al., 
2008). This discrepancy can be explained by our previous reports that highly 
concentrated crude LPS is able to trigger inflammasome formation whereas high 
purity LPS cannot and needs ATP for caspase 1 activation (Martinon et al., 2004). 
Indeed with the crude LPS we used, we could activate caspase 1 formation (Fig. 
4A,B,C).  
 Whether all PARP1-dependent NF-κB target genes are regulated by cleavage 
of PARP1 or whether additional aspects are important, such as structural or epigenetic 
changes, needs to be determined. It was earlier suggested, that PARP1 is unequally 
distributed throughout the chromatin (Jump et al., 1979; Mullins et al., 1977). The 
mechanism by which PARP1 is recruited to gene promoters remains unknown. 
Enrichment of PARP1 at the TSS of different genes under non-stimulated conditions 
has been reported before (Krishnakumar et al., 2008). It is currently not clear whether 
certain histone variants or the positioning of histones is responsible for the enrichment 
of PARP1 at these sites. We have observed in ChIP experiments that PARP1 
recruitment to the IL-6 TSS requires cleavage for full transcriptional activation upon 
LPS stimulation. These results suggest that promoters with PARP1 recruitment might 
also depend on PARP1 cleavage since accumulated PARP1 binding might affect 
chromatin compaction and thereby accessibility for other cofactors.  
 The selection of genes dependent on PARP1 cleavage seems not to be same 
for all tested cell types suggesting that the observed regulatory mechanism is 
dependent on cell type and stimulus. We cannot currently exclude that other caspases 
are also able to cleave PARP1 upon LPS stimulation or another stimulus (e.g. caspase 
6, 7, 8 or 10, Fig. 3B). Therefore, caspase 7 might be activated in combination with 
other caspases (e.g. caspase 6, 8, or 9) to regulate different cellular processes. 
Interestingly, PARP1 cleavage was also observed in extracts of differentiating cells, 
providing additional evidence that PARP1 cleavage is physiologically relevant (Fujita 
et al., 2008). Intriguingly, upon exposure of cells to some bacterial toxins we 
observed PARP1 cleavage (data not shown). It will be interesting to see whether 
activation of other inflammasomes than NALP3 can also lead to PARP1 cleavage and 
link inflammasome activity to transcription.  
 Compaction of chromatin was decreased upon cleavage and dissociation of 
PARP1 from the chromatin (Fig. 5C and 6B). PARP1 was reported to promote the 
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localized compaction of chromatin into supra-nucleosomal structures (Wacker et al., 
2007). The DBD (aa1-373) of PARP1 was necessary and sufficient for binding to 
nucleosomes, yet alone was unable to promote chromatin compaction and could only 
partially repress the chromatin templates. The catalytic domain of PARP1 cooperated 
with the DBD to promote chromatin compaction and efficient transcriptional 
repression in a manner independent of its enzymatic activity. Thus, cleavage of 
PARP1 by caspase 7 might be the physiological link for the observed structural 
changes. Alternatively, cleavage of PARP1 and subsequent release from chromatin 
might not only remove PARP1, but also proteins associated with PARP1. A 
previously identified PARP1 corepressor complex containing nucleolin, 
nucleophosmin, and Hsp70 as well as the N-CoR and HDAC3 corepressors are 
associated with the repressed promoter (Ju et al., 2004). Indeed, we observed protein 
complex formation of PARP1 with HDACs through p24. Caspase 7-mediated PARP1 
cleavage would release p24 and HDACs from the TSS.  
 Whether the enzymatic activity of PARP1 is involved in the caspase 7-
dependent regulation of transcription needs to be further investigated. In our studies, 
DNA stimulated WT and D214N PARP1 to the same extent, excluding that the 
observed difference in gene expression is due to a reduced ADP-ribosylation 
activation of the D214N PARP1 (Figure 5D).  
 In summary, we provide evidence that NALP3 inflammasome activated 
caspase 7 mediates PARP1 cleavage which in turn regulates NF-κB target gene 
expression by altering the chromatin accessibility under sustained inflammatory 
conditions. 
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EXPERIMENTAL PROCEDURES 
 
Mice And Cell Isolation 
C57BL/6, WT and transgenic mice were maintained in a specific pathogen-free 
facility. For the isolation of bone marrow macrophages, 6-8 weeks old mice were 
sacrificed and the cells were isolated as described elsewhere (Pétrilli et al., 2007). 
Cells were plated in 10 cm uncharged plastic plates (`Petri dish`) and incubated for 
full differentiation in RPMI medium supplemented with 10% FCS, 100 units/ml 
penicillin/streptomycin (Gibco), 1x non-essential amino acids (Gibco), 1mM sodium 
pyruvate (Gibco), 50 µM β-mercaptoethanol (Gibco) and 20% L929 conditioned 
medium for 6 days in a humidified incubator (with 5% CO2 at 37°C). At the end of 6 
days, cells were counted and seeded in 6-well tissue culture plates. After 16 hours, 
cells were stimulated with 10 µg/ml LPS for 1 hour and harvested for RNA 
extraction.  
 For the isolation of intraperitoneal cells (IP cells), 6-8 weeks old mice were i.p 
injected with 1mL of 5% thioglycollate brewer medium for four days. Mice were 
sacrificed and cells were collected like described previously (Pétrilli et al., 2004). 
Briefly, cells were collected in RPMI medium by abdominal lavage, washed with PBS 
and seeded at a cell density of 1x106 cells/ml in tissue culture plates in full-RPMI 
medium containing 10% FCS, 100 units/ml penicillin/streptomycin (Gibco), 1x non-
essential amino acids (Gibco) and 1mM sodium pyruvate (Gibco), 50 µM β-
mercaptoethanol (Gibco). Cells were cultured in full-RPMI medium. Animal 
experiments were performed according to the regulations of the cantonal veterinary 
office. 
 
RNA Extraction And Gene Expression Analysis By Real-Time RT-PCR 
Sub-confluent (50%) cells were stimulated with 10 µg/ml LPS for one hour. Total 
RNA was isolated using ‘Total RNA isolation mini kit’ (Macherey-Nagel), except 
from total RNA from primary bone derived macrophages, which was isolated using 
Ambion RNAqueous®-Micro Kit. RNA was subsequently reverse-transcribed using 
the ‘High-capacity cDNA reverse transcription kit’ (Applied Biosystems). Real-time 
PCR was performed using the Rotor-Gene 3000 (Corbett Life Science, now Qiagen) 
and TaqMan assays or SYBR Green using the primers listed in Table S1 and S2. 
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Mean value ± SE was calculated and blotted into graphs with GraphPad Prism 
(GraphPad Software).  
 
Transient Transfections 
THP1 cells were primed with PMA (10ng/mL) for 24 hours and were transfected with 
30 pmol siRNA oligos (Qiagen) with 4 µl Lipofectamine RNAimax reagent 
(Invitrogen) according to manufacturer`s protocol for two days. Transfection into 
HEK293 cells was described elsewhere (Hassa et al., 2005).  
 
Stable PARP1 Knockdown And Complementation In THP1 Cells 
Generation of viruses and transduction of cells was done as described earlier (Ariumi 
et al., 2005). Briefly, pRDI vector containg PARP1 shRNA (#5) was used to 
transduce THP1 cells. The short hairpin RNA was against 5`UTR region of PARP1 
mRNA. Transduced cells were selected through puromycin resistance gene. 
Complementation of cells was done with pRRL-myc-PARP1 vectors containing a 
blasticidin resistance marker and complemented cells were subsequently selected for 
three weeks with 2 µg/ml blasticidin. 
 
Chromatin Immunoprecipitation 
Cells were crosslinked with either 1% formaldehyde (Calbiochem) or with 
formaldehyde and the protein crosslinking agent dimethyl 3,3`-DTBP (Kurdistani and 
Grunstein, 2003). Chromatin fragmentation was achieved with the Bioruptor 
(Diagenode). Antibodies were incubated with crosslinked chromatin overnight at 4°C 
and collected with Protein A Agarose/salmon sperm DNA (Milipore) for 3 hours. 
After reversal of the crosslink and digestion with proteinase K, DNA was extracted 
and measured by real-time PCR using SYBR Green and the Rotor-Gene 3000 
(Corbett Life Science, now Qiagen). Primers used for ChIP RT-PCR analysis are 
listed in table S3. 
 
Chromatin Accessibility By Real-Time PCR  
Accessibility of DNA to MNase was analyzed using chromatin accessibility by real-
time PCR (CHART-PCR) as described elsewhere (Rao et al., 2001). The genomic 
DNA was isolated using a `Mammalian Genomic DNA miniprep kit` (Sigma). 
Primers used in real-time PCR analysis are listed in table S3. 
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SUPPLEMENTAL DATA 
 
Supplemental data include 4 figures, 3 tables and Supplemental Experimental 
Procedures. 
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FIGURE LEGENDS  
 
Fig. 1. Induction of a Subset of NF-κB Genes is Compromised in D214N PARP1 
IP Cells 
(A) PARP1 cleavage is induced by LPS stimulation. Peritoneal macrophages from 
wild-type and D214N mice were stimulated for the indicated times with 10 µg/ml 
LPS. Total cell extracts were analyzed by western blot (B) Gene expression profile of 
CSF2, IL-6, LIF, IP-10 in intraperitoneal cells (IP cells) isolated from WT and D214N 
PARP1 mice. Cells were stimulated with LPS for one hour and mRNA levels were 
determined by real-time RT-PCR analysis. Samples were normalized to Rps12 
expression levels and expressed as fold increase relative to unstimulated mRNA 
levels. Data are means of ±SEM at least four independent experiments. (C) Analysis 
of p65 recruitment to target promoters by chromatin immunoprecipitation. IP cells 
were stimulated with LPS 30 or 60 minutes. Recruitment to indicated promoters was 
analyzed by real-time RT-PCR. Results were expressed as fold increase relative to 
unstimulated p65 occupancy levels. Prolactin promoter served as a negative control. 
Data are means of ±SEM of at least three independent experiments. 
 
Fig. 2. LPS Induced PARP1 Cleavage Regulates the Expression of IL-6 in THP1 
Cells 
(A) PARP1 cleavage profile in LPS treated THP1 macrophages. Total cell extracts 
were prepared and analyzed by western blot using indicated antibodies. (B) LPS 
stimulation does not affect cell viability. THP1 macrophages were stimulated with 
LPS for the indicated times and stained with calcein and ethidium homodimer. Cells 
were analyzed by immunofluorescent microscopy. (C) Stable knockdown of PARP1 
in THP1 monocytes using a lentiviral system. shRNA against PARP1 targets the 5` 
untranslated region of PARP1 mRNA. (D) Stable complementation of THP1 PARP1 
knockdown cells either with PRRL-empty vector, myc-tagged WT PARP1 or 
uncleavable PARP1 D214N mutant. Total cell extracts were prepared and proteins 
were immunoprecipitated with a myc antibody and analyzed by western blot using 
PARP1 antibody. Gapdh was used as loading control. (E) Gene expression profile of 
IL-6, IP-10 and COX-2 in stably complemented THP1 cells. Cells were stimulated 
with LPS for one hour and mRNA levels were determined by real-time RT-PCR 
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analysis. Samples were normalized to Rpl28 expression levels and expressed as fold 
increase relative to unstimulated mRNA levels. Data are means of ± SD, n=2. Ctrl* is 
the sample treated with Etoposide for 16 hours. 
 
Fig. 3. Caspase 7 Knock-down Reduces LPS Dependent NF-κB Target Gene 
Response  
(A) Pan caspase inhibitor Z-VAD-fmk blocks PARP-1 cleavage. Bone-marrow 
derived macrophages from wild-type mice were stimulated with LPS for different 
times in the absence or presence of Z-VAD-fmk (50 µM). Total cell extracts were 
prepared and PARP1 cleavage was analyzed by western blot. (B) Screening caspase 
family (one-ten) for PARP1 cleavage at D214 in vitro. Either in vitro translated and 
35S labeled PARP1 WT or D214N mutant plasmids (upper blot) or recombinant 
PARP1 WT or D214N mutant recombinant proteins (lower blot) were incubated with 
active caspases (1-10) for 20 minutes at 30°C in a caspase cleavage buffer. Reaction 
products were analyzed by SDS gel followed by autoradiography (upper blot) or 
western blot using PARP1 antibody (lower blot). (C and D) Effect of caspase knock-
down on LPS dependent NF-κB target gene response. IP cells (C) or complemented 
THP1 cells (D) were transiently transfected with the indicated siRNA oligos and gene 
expression was analyzed by real-time RT-PCR. (C) Samples were normalized to 
Rps12 and expressed as fold increase relative to unstimulated mRNA levels. Data are 
means of ± SD, n=2. (D) Samples were normalized to Rpl28 expression levels and 
increase in gene expression to LPS was expressed as fold response. Fold response was 
set arbitrarily as 100% in simock transfected cells. Data are means of ± SD, n=2. (E) 
THP1 cells were stimulated with LPS (10µg/ml) for the indicated times. Cells were 
then fractionated and cytoplasmic and nuclear extracts were subjected to western 
blotting with antibodies directed against Caspase-7 (full-length and cleaved form), 
PARP1 and tubulin.       shows the cleaved p89 PARP1 fragment. 
 
Fig. 4. Caspase 7 Is Target of NALP3 Inflammasome 
(A) PARP1 cleavage upon LPS stimulation is mediated by caspase 1 and caspase 7. 
Peritoneal macrophages from wild-type, caspase 1 -/- and caspase 7 -/- mice were 
stimulated for the indicated times with LPS, total cell extracts were prepared and 
PARP1 cleavage, caspase 1 and caspase 7 activation was analyzed by western blot. 
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(B) Caspase 7 activation upon LPS stimulation is impaired in the absence of NALP3. 
Bone-marrow derived macrophages from wild-type and NALP3 -/- mice were 
stimulated for the indicated times with LPS, total cell extracts were prepared and 
caspase 1 and caspase 7 activation was analyzed by western blot.. (C) PARP1 
cleavage upon LPS stimulation is impaired in the absence of ASC. Peritoneal 
macrophages from wild-type and ASC -/- mice were stimulated for the indicated times 
with LPS, total cell extracts were prepared and PARP1 cleavage, caspase 1 and 
caspase 7 activation was analyzed by western blot. (D) Uncleavable PARP1 (D214N) 
does not interfere with caspase activation by LPS. Peritoneal macrophages from wild-
type and D214N PARP1 mice were stimulated for the indicated time with LPS, total 
cell extracts were prepared and PARP1 cleavage, caspase 1 and caspase 7 activation 
was analyzed by western blot. 
 
Fig. 5. PARP1 Dissociates from the Promoters of Target Genes  
 (A and B) PARP1 interacts with HDAC1 and 2 through its ZF domain in vivo. 
FLAG-tagged HDACs and Myc-tagged PARP1 full-length (FL), PARP1 (p89) or 
PARP1 (p24) fragments were co-expressed in HEK 293 cells. PARP1 complexes 
were co-immunoprecipitated (IP) from nuclear extracts of untreated HEK 293 cells 
using an anti-Myc antibody and subsequently tested for Myc-tagged PARP1 and 
FLAG-tagged HDAC-1 (A) and HDAC-2 (B) by western blot analysis using anti-Myc 
and anti-FLAG antibodies. (C) Chromatin immunoprecipitation analysis of PARP1 
occupancy upon LPS stimulation on the target promoters. WT and D214N PARP1 
complemented THP1 cells were stimulated with LPS for 60 minutes. PARP1 was 
immunoprecipitated with a myc antibody and the occupancy on the indicated 
promoters was measured by qRT-PCR. Results are corrected for the input controls 
and expressed as relative occupancy, unstimulated levels being set arbitrarily as 1. 
H2B promoter was assessed as negative control. Data are means of ± SD, n=2. (D) 
Enzymatic activity of recombinant PARP1 proteins. WT, D214N, E988K PARP1 
baculo virus generated proteins were incubated with DNA for 5 minutes and 
ribosylation was analyzed by autoradiography. (E) Interaction of PARP1 fragments 
with GST-p65. GST-p65 recombinant protein purified from insect cells was incubated 
with cleaved (p24, p89) and full-length WT and D214N PARP1 proteins. Interaction 
was analyzed by western blot.  
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Fig. 6. PARP1 Cleavage by LPS enhances Chromatin Accessibility around TSS  
 (A) Gene expression profile of CSF2, NOS-2, IP-10 and MIP-2 in bone marrow 
derived macrophages (BMDM) isolated from WT and D214N PARP1 mice. Cells 
were stimulated with LPS for one hour and mRNA levels were determined by real-
time RT-PCR analysis. Samples were normalized to Rps12 expression levels and 
expressed as fold increase relative to unstimulated mRNA levels. Data are means of 
±SEM three independent mice groups where each group contains two mice, n=6. (B) 
Chromatin accessibility by real-time PCR (CHART-PCR) in BMDMs. Nuclei from 
unstimulated and LPS stimulated BMDMs were incubated with MNase. (-1) kb 
upstream promoter and TSS of CSF2, NOS-2 was analyzed by qRT-PCR. Results 
were expressed as uncut over cut genomic DNA and normalized to unstimulated 
levels. Unstimulated uncut / cut genomic DNA levels around TSS was arbitrarily set 
as 100. Data are from a pool of 6 mice and means of ± SD, n=2. 
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SUPPLEMENTAL DATA 
 
SUPPLEMENTAL TABLES 
Table S1, S2, S3: PCR primers used in this study. The sequences of forward (F) and 
reverse (R) primers used for PCR are given in 5`-3`direction. 
 
TABLE S1. SyBr green primers used in real-time RT-PCR analysis 
Gene  Species Sequence (F, R; 5`-3`) 
CSF2 Mus musculus ACATGCCTGTCACGTTGAAT 
TTGAGTTTGGTGAAATTGCC 
IP-10 Mus musculus GCACGAACTTAACCACCATCTTCC 
CTACCCATTGATACATACTTGATGACAC 
IL-6 Mus musculus ACTGACAATATGAATGTTGGGACAC 
ACCATCTGGCTAGGTAACAGAA 
MIP2 Mus musculus ACATCCCACCCACACAGTGAAAGA 
TCCTTCCATGAAAGCCATCCGACT 
LIF Mus musculus CCATAGATGCAGCAAGGAGA 
CAGTCCTGAGATGAGCCTGA 
RPS12 Mus musculus GAAGCTGCCAAAGCCTTAGA 
AACTGCAACCAACCACCTTC 
RPL28 Homo Sapiens GCAATTCCTTCCGCTACAAC 
TGTTCTTGCGGATCATGTGT 
IL-6 Homo Sapiens GGCACTGGCAGAAAACAACC 
GCAAGTCTCCTCATTGAATCC 
 
TABLE S2. Taqman probes used in real-timer RT-PCR analysis 
Gene  Species Taqman-Number 
NOS-2 Mus musculus Mm00440485 
CALNEXIN Mus musculus Mm00500330_m1 
IP-1O Homo Sapiens Hs00171042_m1 
CSF2 Homo Sapiens Hs99999044_m1 
COX-2 Homo Sapiens Hs00153133_m1 
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TABLE S3. SyBr green primers used in ChIP and CHART RT-PCR analysis 
Gene  Species Sequence (F, R; 5`-3`) 
IP-10 Mus 
musculus 
GCAATGCCCTCGGTTTACAG 
GGCTGACTTTGGAGATGACTCA 
IL-6 Mus 
musculus 
CCCCACCCTCCAACAAAGATTTT 
CCCCAGTCTCATATTTATTAGGAGTCAAC 
CSF2 Mus 
musculus 
AATTCTGCAGCCACATCCTC 
GCCAGGAGATTCCACAACTC 
CSF2(-1KB) Mus 
musculus 
CTTGAGACCATGCTGCCTTT 
GCTTCCCTGGCAAGTTCTC 
NOS-2 Mus 
musculus 
ATGGCCTTGCATGAGGATAC 
GCAGCAGCCATCAGGTATTT 
NOS-2  
(-1KB) 
Mus 
musculus 
GGGTGTTGCCTGGATAAAGA 
CACTTGCACACACACACAGC 
Prolactin Mus 
musculus 
CCTTCATTTCTGGCCAATGT 
GCCTGAGAGAACCACAGCTT 
IL-6 Homo 
Sapiens 
CCTCACCCTCCAACAAAGAT 
GCCTCAGACATCTCCAGTCC 
H2B Homo 
Sapiens 
TTGCATAAGCGATTCTATATAAAAGCG 
ATAAAGCGCCAACGAAAAGG 
 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Tissue Culture 
THP1 monocytic cells were grown in suspension and maintained in RPMI 
supplemented with 10% FCS, 1mM sodium pyruvate (Gibco), 1x non-essential amino 
acids (Gibco) and 100units/ml penicillin/streptomycin (Gibco), 50 µM β-
mercaptoethanol (Gibco) at a cell density of 0.3 to 1.0x106/mL. For differentiation 
into macrophages, cells were plated at a density of 1x106/6-cm dish in RPMI with 10 
ng/ml PMA for 18 hours to become fully differentiated macrophages before use in 
experiments. HEK 293 cells were maintained in DMEM supplemented with 10% FCS 
and 100 units/ml penicillin/streptomycin. All cells were maintained at 37°C in 5% 
CO2. 
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 Plasmids  
Plasmid for the mammalian expression of human PARP1 was generated by cloning 
human PARP1 cDNA into XhoI cloning site of pCDNA 3 with a hemagglutinin-tag at 
the C-terminus. Corresponding D214N PARP1 mutant was generated by site directed 
mutagenesis and confirmed by sequencing. Plasmids for the mammalian expression of 
HDAC 1-2 were described elsewhere (Hassa et al., 2005). myc-PARP1(WT), myc-
PARP1 (89 kDa), myc-PARP1 (24 kDa) were cloned into pCMV vector and the latter 
two constructs had a nuclear localization signal at the N-terminus. 
 
Reagents and Antibodies 
Lipopolysaccharide (LPS, 055:B5) was purchased from Sigma. Active recombinant 
human caspase Set IV was purchased from Biovision. Etoposide was purchased from 
Calbiochem. Ethidium homodimer and Calcein AM were purchased from Fluka. 
SyBR Green was purchased from Quantace. The following antibodies were purchased 
from Santa Cruz Biotechnologies: anti-RelA (sc-372), anti-PARP1 (sc-7150), anti-
GAPDH (FL-335), anti-caspase 7 (sc-28295). The anti-PARP1 (89) and active-
caspase 7 (9491) antibodies were from Cell Signaling. Anti-mouse caspase-1 was 
obtained from Peter Vandernabele. The anti-myc antibodies were either purchased 
from Roche (11-667-149-001) or purified from hybridoma cells. The anti-Tubulin and 
anti-Flag (M2) antibodies were purchased from Sigma and the anti-HA was from 
Covance (MMS-101P). 
 
Generation Of Recombinant Proteins  
The recombinant proteins were expressed by baculovirus in Sf21 cells using either the 
FastBac (Invitrogen) or the BacPAK systems (Clontech). His-tagged proteins were 
purified over Ni2+-beads (ProBond, Invitrogen) and GST-tagged proteins over L-
Glutathione beads (Sigma). All purified proteins were analyzed by coomassie staining 
and confirmed by western blot analysis using the corresponding antibodies.  
 
32P- NAD Automodification 
Experiment was performed as described elsewhere (Altmeyer et al., 2009). 
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In Vitro Translation 
HA-tagged WT and D214N mutant PARP1 were in vitro translated using the `TNT 
couped reticulocyte lysate systems` (Promega) following the manufacturer’s 
instructions. 
 
In Vitro PARP1 Cleavage Assay 
10 pmol recombinant or 125 ng in vitro translated 35S labeled WT or D214N PARP1 
proteins were incubated for 20 minutes at 37°C with 1U of recombinant caspases in 
caspase cleavage buffer (50 mM Hepes pH 7.2, 50 mM NaCl, 0.1% Chaps, 10 mM 
EDTA, 5% Glycerol, 10 mM DTT). Proteins were subsequently resolved by SDS-
PAGE and analyzed by western blot or autoradiography. 
 
In Vitro Interaction and GST Pull-Down Assays 
GST-p65 expressed in insect cells was immobilized on glutathione-sepharose beads 
(Amersham Biosciences) and incubated with recombinant PARP1 proteins (WT, 
D214N mutant, p24 or p89 PARP1 fragments) in binding buffer (50 mM Tris pH 8, 
100 mM NaCl, 0.5% NP-40, 5 mM DTT, 1 mM PMSF) for 2 h at 4°C rolling. 
Glutathione beads were washed three times with precission buffer (50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1mM EDTA, 1 mM DTT) and incubated with precission 
enzyme in 50 ul precission buffer overnight. Proteins in the supernatant were boiled, 
resolved on SDS-PAGE and subjected to western blot using anti-PARP1 or anti-HA 
antibodies. 
 
Whole Cell Extract and Immunoprecipitation for Myc-PARP1 
Unless stated otherwise, whole cell extracts were prepared by lyzing the cells for 15 
minutes in lysis buffer (50 mM Tris pH 8, 500 mM NaCl, 1% Triton X-100, 1µg/ml 
pepstatin, 1µg/ml bestatin, 1µg/ml leupeptin, 2 mM PMSF) at 4°C. One milligram of 
whole cell extract was incubated with anti-myc antibody for 2 hours at 4°C. 
Immunocomplexes were collected with Protein A agarose beads (GE Healthcare) for 
1 hour at 4°C and washed three times with wash buffer containing 120 mM NaCl. 
Immunocomplexes were analyzed by standard western blot analysis using anti-
PARP1 and anti-GAPDH antibodies.  
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Nuclear Extract Preparation  
Cells were stimulated with 10 µg/ml LPS for the indicated times, washed with PBS, 
harvested and washed again three times in buffer A (10 mM HEPES KOH pH7.9, 1.5 
mM MgCl2, 10 mM KCl, 1µg/ml pepstatin, 1µg/ml bestatin, 1µg/ml leupeptin, 2 mM 
PMSF, 5mM DTT). Cells were lysed with A+ buffer (Buffer A+ 0.06 % NP-40) and 
centrifuged for 5 minutes at 5000 rpm. Supernatant corresponding to cytoplasm was 
saved for western blot analysis. Pellet was washed three times with buffer A and 
subsequently resuspended in three volumes of Buffer C (20 mM HEPES KOH pH7.9, 
0.42 M NaCl, 1.5 mM MgCl2, 25% v/v glycerol, 1µg/ml pepstatin, 1µg/ml bestatin, 
1µg/ml leupeptin, 2 mM PMSF, 5 mM DTT) and incubated for 15 minutes at 4°C on 
rotating wheels. Lysate was centrifuged for 10 minutes at 4°C at 14000 rpm with the 
supernatant corresponding to the nuclear fraction.150 µg cytoplasmic extracts and 50 
µg nuclear extracts were boiled with Laemmli buffer, resolved on 15% SDS-PAGE 
and subjected to western blot using different antibodies. 
 
Cell Viability Assay 
THP1 macrophages stimulated with 10 µg/ml LPS for the indicated times were 
incubated with 4 µM Ethidium homodimer and 2 µM Calcein mix in PBS for 30 
minutes at 37°C incubator. Ethidium homodimer positive and Calcein positive  cells 
were visualized using Olympus BX51 microscope.  
 
In Vitro Inflammasome Formation  
Peritoneal macrophages were primed overnight with 100 ng/ml of ultra-pure LPS and 
stimulated as indicated asbestos (150 mg/ml), MSU (150 mg/ml), R837 (10 mg/ml), 
Nigericin (20mM) for 6hr except ATP 5mM 30’ (Pétrilli et al., 2007). 
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SUPPLEMENTAL FIGURES 
 
Fig. S1. LPS Stimulation Leads to PARP1 Cleavage 
(A) Interaction of PARP1 with p65 in WT and D214N PARP1 IP cells. WT and 
D214N PARP1 IP cells were stimulated with LPS for 30 minutes and nuclear extracts 
were prepared. PARP1 complexes were co-immunoprecipitated (IP) using an anti-
PARP1 antibody and subsequently tested for PARP1 and p65 by western blot analysis 
using anti-PARP1 and anti-p65 antibodies. (B) THP1 monocytes were stimulated with 
LPS for different times, total cell extracts were prepared from and analyzed by 
western blot using antibodies against the full-length and cleaved C-terminal fragment 
of PARP1 (p89) and Tubulin as loading control. (C) PARP1 cleavage in 
complemented THP1 cells. THP1 cells were stimulated with campothethcin (CPT), 
total cell extracts were prepared and proteins were analyzed by western blot using the 
indicated antibodies. (D) CHX does not interfere with PARP1 cleavage induced by 
LPS. Bone-marrow derived macrophages from wild-type mice were  stimulated with 
LPS in the presence or absence of CHX for different time points. Total cell extracts 
were prepared and PARP1 cleavage was analyzed by western blot using PARP1 
antibody that recognizes the cleaved large fragment (p89). 
 
Fig. S2. Caspase 7 Knock-down Reduces NF-κB Response to LPS in THP1 Cells  
 (A) THP1 cells were transiently transfected with mock, caspase 3 or caspase 7 
siRNA oligos for two days. Cells were stimulated with LPS for one hour and mRNA 
levels were determined by real-time RT-PCR analysis. Samples were normalized to 
Rpl28 expression levels and increase in gene expression to LPS was expressed as fold 
induction. Data are means of ± SD, n=2. (B) Caspase 7 knock-down in THP1 cells. 
THP1cells complemented with WT or D214N PARP1 were PMA primed, transfected 
with mock or caspase 7 siRNA oligos for two days, total cell extracts were prepared 
and subjected to western blotting using the indicated antibodies. 
 
Fig. S3. Absence of Caspase 7 Does Not Effect Inflammasome Activation  
(A) Peritoneal macrophages from WT and caspase 7 -/- mice were activated with 
different inflammasome activators, cell supernatants and cell extracts were prepared, 
IL-1β secretion and caspase 1 activation was analyzed by western blot. 
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 Fig. S4. PARP1 Cleavage by LPS Enhances Chromatin Accessibility around TSS 
in IP Cells 
Chromatin accessibility by real-time PCR (CHART-PCR) in IP cells. Nuclei from 
unstimulated and LPS stimulated BMDMs were incubated with MNase. (-1) kb 
upstream promoter and TSS of CSF2 was analyzed by qRT-PCR. Results were 
expressed as uncut over cut genomic DNA and normalized to unstimulated levels. 
Unstimulated uncut / cut genomic DNA levels around TSS was arbitrarily set as 100. 
Data ± SE are from three independent experiments. 
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 SUMMARY 
Deregulated glucose homeostasis leads to obesity, which is associated with 
chronic low-grade inflammation that negatively impacts insulin sensitivity. Here, 
we show that PARP1 knockout mice in the C57BL/6 background develop obesity 
and display decreased energy expenditure on normal diet when compared to 
their wild type littermates. Obese PARP1-/- mice show elevated expression of 
proinflammatory cytokines like IL-6, IP-10, MCP1 and TNFα  in adipose tissues 
and develop insulin resistance. In liver, PDK4 and G6Pase two important genes 
involved in glucose homeostasis are upregulated in PARP1-/- mice. Interestingly 
young PARP1-/- mice preserve insulin signaling, but have already increased 
glucose levels, suggesting a regulatory role of PARP1 in the transcriptional 
regulation of genes involved in gluconeogenesis and glucose homeostasis. 
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 Introduction 
The liver is a central regulator of glucose homeostasis and stores or releases glucose 
according to metabolic demands. In insulin resistant states or diabetes the 
dysregulation of hepatic glucose release contributes significantly to the 
pathophysiology of these conditions. Type 2 diabetes mellitus is characterized by both 
insulin resistance as manifested by reduced insulin-stimulated glucose uptake in 
skeletal muscle and adipose tissue, inappropriately high hepatic glucose output and 
reduced insulin secretion by pancreatic β-cells [1-3]. Although the specific molecular 
pathophysiology remains unclear, many risk factors have been identified for Type 2 
diabetes mellitus, including family history of diabetes and prominent environmental 
factors such as excessive food intake leading to obesity, alterations in early life 
development, decreased physical activity and aging [1, 3, 4].  
 At the cellular level, multiple regulatory mechanisms and metabolic pathways 
may contribute to the pathogenesis of insulin resistance, potentially mediated by 
alterations in insulin receptor signaling [5], mitochondrial oxidative metabolism and 
ATP production [6-8], fatty acid oxidation [9], or proinflammatory signaling [10]. 
Insulin drives the global anabolic response to nutrient ingestion, regulating both 
carbohydrate and lipid metabolism. Insulin binds to insulin receptor to activate a 
cascade of intracellular signaling events [11], including the MAPK pathway, which 
mediates various cellular effects, such as growth and mitogenesis; the PI3K–Akt 
pathway, which controls gluconeogenesis, glycogen and protein synthesis via 
regulation of mammalian target of rapamycin (mTOR), forkhead box O1 (FOXO-1) 
and others; and the c-Cbl-associated protein (CAP)/Cbl and small G protein TC10 
pathway that regulates glucose transporter 4 (GLUT-4) and uptake of glucose into 
adipocytes and muscle [12]. The prevalent model of hepatic insulin signaling is that 
activated Akt phosphorylates and inhibits the transcription factor FoxO, peroxisome 
proliferator-activated receptor-coactivator-1a (PGC-1a), and others, thereby 
terminating expression of the rate-controlling enzymes of gluconeogenesis [13, 14]. 
Another important aspect of the control of hepatic glucose metabolism is neuronal 
insulin signaling. Insulin’s effect on the liver seem to depend largely on a primary 
insulin action in the brain. Neuron-specific insulin receptor disrupted (NIRKO) mice 
were found to develop mild insulin resistance and elevated plasma insulin levels in 
association with obesity (Brüning and Kahn 2000).  
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  Poly(ADP-ribose) polymerase-1 (PARP1) is an abundant and ubiquitous 
nuclear enzyme that catalyzes the nicotinamide adenine dinucleotide (NAD+)-
dependent addition of ADP-ribose polymers on a variety of target proteins [15]. It has 
been implicated in diverse biological processes, including transcriptional regulation, 
chromatin remodeling, DNA repair, cell proliferation, and apoptosis [15, 16]. In 
transcription, PARP1 acts as transcriptional cofactor (either a coactivator or a 
corepressor) for a variety of transcription factors. The enzymatic activity of PARP1 
was described to be required for some transcription factors (e.g., HES1, NFAT, and 
p53) [17-19], while for others it is not required (e.g., NF-κB, B-Myb, and retinoic 
acid receptor) [20-22]. Loss of PARP1 is shown to affect gene expression profile in a 
genome-wide manner [23]. Although young PARP1-/- mice display no phenotypic 
abnormalities, older mice originating from a mixed genetic background 
(129/Sv×C57BL/6) were susceptible to epidermal hyperplasia and obesity, suggesting 
an important role for PARP1 in general metabolism [24]. This study is supported by 
data demonstrating that PARP1-/- female mice on 129 back-ground older than 21 
months gained body weight more than their wild-type litter mates when fed a normal 
diet [25] and that PARP1-/- on the 129 back ground mice are highly susceptible to 
diet-induced obesity, accumulate more fat tissue and develop hyperleptinemia and 
insulin resistance and glucose intolerance compared to their wild type counterparts 
[26]. 
 Here, we present an in vivo model that PARP1 is regulating glucose 
homeostasis through the regulation of the expression of genes involved in 
gluconeogenesis in the C57BL/6 background on normal diet, which with age leads to 
obesity and obesity induced inflammation. 
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 RESULTS 
 
PARP1 Knockout Mice Display Increased Weight Gain and Decreased Energy 
Expenditure on Chow Diet Compared to Their Wild Type Counterparts 
PARP1 was described to regulate gene expression and cellular NAD+, the substrate of 
PARP1, was described to alter upon diet.  We sought to investigate whether PARP1 
plays a role in energy metabolism. Wild type (WT) and PARP1 knock-out (-/-) mice, 
at the age of 6-8 weeks were either fed with normal chow diet (ND) or high-fat diet 
(HFD) [24]. 6 weeks after the start of experiments, PARP1-/- mice on ND weighed 
significantly more than WT on the same ND (Fig. 1A,B). However, at the end of the 
experiments WT mice on HFD weighed 20g more than the WT on ND whereas 
PARP1-/- mice on HFD weighed only 11g more than the PARP1-/- mice on ND. 
These results suggest that PARP1 under normal physiological conditions helps to 
maintain energy metabolism but its absence might protect from obesity under HFD. 
Surprisingly, 6 weeks after the start of experiments, body weight, circulating levels of 
glucose differed significantly PARP1-/- mice and their wild-type littermates on ND  
but not in HFD (Fig. 1C). Although mice on HFD gained more weight and had higher 
glucose levels compared to mice on ND, no significant difference was observed 
between the genotypes after 6 weeks (Fig. 1C). 
 Body weight represents a net balance of food intake and energy expenditure. 
Leptin is an important player involved in regulating energy intake and energy 
expenditure [27]. HFD after 13 weeks increased serum leptin levels by 80 fold in 
wild-type mice (Fig. 2A). No difference was detected between WT and PARP1-/- 
mice on HFD.  Interestingly, PARP1-/- mice on ND had higher leptin levels than WT. 
At this age (19 weeks), the body weight of WT and PARP1-/- mice on ND differed 
statistically, even more than 12 weeks old mice (see Fig. 1A). Paradoxically, PARP1-
/- on ND showed lower daily food intake per body weight compared to wild-type 
mice, perhaps due to higher circulating leptin serum levels (Fig. 2B). Energy 
expenditure (EE) was similar in WT and PARP1-/- mice on HFD whereas on ND 
PARP1-/- mice tended to have lower EE than WT mice (Fig. 2C). This difference was 
significant in dark phase. We also compared the respiratory quotient (RQ = 
VCO2/VO2), as a measure of fuel-partitioning patterns. RQ fluctuated between 0.85 
and 1.0 in mice on a ND, and fluctuated between 0.8 and 0.9 in mice on HFD for both 
genotypes (Fig. 2D). No effect for genotype was observed neither under ND nor 
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 HFD, suggesting that there was no difference in fuel selection between carbohydrates 
and lipids for WT and PARP1-/- mice.  
 
PARP1 Knock-Out Mice Display Deteriorated Glucose Homeostasis 
Differences in glucose homeostasis between PARP1-/- and WT mice were most 
pronounced under ND. This effect seemed to vanish when mice were fed with HFD. 
Since PARP1-/- had increased glucose levels, we investigated whether PARP1 might 
play a role in glucose homeostasis. We performed intraperitoneal (IP) glucose and 
insulin tolerance tests after 3 months of exposure of mice to ND or HFD. Chronic 
exposure to HFD increased fasting glucose levels (Fig. 3A compare right-left panel, 0 
min). Interestingly, PARP1-/- mice on ND were glucose intolerant  compared to WT. 
A similar trend was also observed in mice under HFD although the difference 
between WT and PARP1-/- mice was less marked. Intolerance to glucose in PARP1-/- 
mice was not due to reduced insulin levels, since PARP1-/- mice had even higher 
insulin levels (Fig. 3B). Furthermore, PARP1-/- mice on ND but also on HFD had a 
lower sensitivity to IP insulin compared to WT mice (Fig.3C). 
 PARP1-/- mice had comparable fed free fatty acid and cholesterol serum 
levels on HFD and ND (Fig. 3D), which were similar to wild-types, suggesting that 
the lipid homeostasis was not affected by the lack of PARP1. 
 
Old PARP1-/-  Mice Are Prone to Obesity-Induced Inflammation  
At the age of 19 weeks PARP1-/- mice on chow diet weighed significantly more than 
WT (Fig. 1A,B). Obesity leads to an increase in tissue inflammation, particularly 
within adipose tissue [28, 29]. Large numbers of macrophages accumulate in fat 
depots in obese mice and human [30, 31]. Tissue macrophages recruited to adipose 
tissue in obese animals exhibit increased expression of proinflammatory genes 
including TNF-α and IL-6. Blocking the functions of these macrophages result in a 
more glucose tolerant, insulin sensitive state [28, 32]. We investigated whether obese 
mice had increased inflammatory gene expression in white adipose tissue (WAT). As 
expected, HFD elevated the mRNA expression of proinflammatory cytokines like IL-
6, IP-10, MCP1 and TNF-α but no effect for genotype was observed on HFD except 
for IL-6 (Fig. 4A). Because body weight matched controls were not included, we 
speculate that this might reflect the small difference in body weight between WT and 
76
 PARP1-/- under HFD. However, PARP1-/- on ND had significantly increased 
proinflammatory gene expression in comparison to WT, supporting the conclusion 
that these mice are obese and prone to inflammation. We have previously reported 
that PARP1 activates NF-κB gene expression [20]. The increased inflammatory gene 
response in older PARP1-/- mice on ND is therefore more likely to be secondary to 
the developed obesity. Next, we analysed PPARγ target gene expression in WAT. 
While the overall expression levels of PPARγ were not altered under the tested diets, 
we observed that HFD increased the expression of CD36 and decreased Glut4 
expression levels in both genotypes (WT and PARP1-/-) (Fig. 4B). Genotypic 
expression differences were only observed for PARP1-/- mice fed with ND.  These 
results indicated that gene expression profiles WAT of obese PARP1-/- mice  also 
displayed differential expression of PPARγ target genes.  
 
Insulin Regulated Gene Expression Is Affected in Liver 
Next we examined the expression profiles in liver from ND and HFD mice. No 
significant difference was observed for liver weights when normalized to body weight 
(Fig. 5A). In addition, PARP1 protein level was not dependent on the diet (Fig. 5B).  
 We analysed hepatic gene expression by real-time RT-PCR. Hepatic PPARγ 
and target gene CD36 was greatly induced in PARP1-/- mice on ND in comparison to 
WT controls (Fig. 5C). In contrast, Glut4 levels were decreased in PARP1-/- mice on 
ND and for both genotypes on HFD, indicating that the expression levels for Glut4 
might be additionally regulated by the obesity. In addition, while genes involved in β-
oxidation such as PPAR-α, ACOX, CPT1, MCAD were slightly reduced in mice on 
HFD, were unchanged when compared between the two genotypes (Fig. 5D). 
Interestingly, two genes involved in glucose homeostasis, pyruvate dehydrogenase 
kinase isoform 4 (PDK4) and glucose-6-phosphatase (G6Pase) were strongly 
upregulated in PARP1-/- mice on ND, but not on HFD, whereas insulin receptor (IR) 
expression was comparable in both genotypes (Fig. 5E). PDK4 and G6Pase 
expression was reported to be inhibited by the insulin signaling under physiological 
conditions. Despite the elevated levels of insulin in PARP1-/- mice on ND, PDK4 and 
G6Pase levels were not reduced, suggested an increase gluconeogenesis and glucose 
serum levels in this genotype. Together, these results indicate that PARP1 might 
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 regulate glucose homeostasis by regulating expression of enzymes involved in 
glucogeonesis.  
 
Young PARP1-/-  Mice Preserve Insulin Signaling 
To investigate the mechanisms by which the targeted PARP1 gene disruption affects 
glucose homeostasis which would, under chronic conditions, lead to obesity in mice 
on ND, we performed glucose and insulin tolerance in young mice (6 weeks old) on 
ND. At this age body weight and fasting glucose levels were comparable. GTT 
indicated that the overall uptake of glucose serum levels is only slightly reduced in 
PARP1-/- mice (Fig.6A). ITT experiments revealed that fed glucose levels were 
increased in PARP1-/- mice, but that the insulin induced uptake was comparable 
between the two tested genotypes (Fig. 6B). To further strengthen the observation that 
the insulin signaling is not altered and not the cause for the observed obesity in 
PARP1-/- mice on ND, liver extract from both wild-type and PARP1-/- mice fed on 
ND, was generated 10 minutes after injection of insulin. Liver extracts were 
subsequently analyzed by immunoblot for Akt phosphorylation. PARP1-/- mice 
exhibited normal insulin-stimulated Akt phosphorylation compared to WT mice (Fix. 
6D). Comparable insulin signaling through Akt phosphorylation could also been 
confirmed in WAT or muscle tissues of PARP1-/- and WT mice (Fig.6C and E). In 
addition Glut4 levels were comparable in WT and  PARP1-/-  muscle extracts, 
suggesting that Glut4 levels is less likely to be the cause for the observed impaired 
glucose homeostasis in PARP1-/- mice. Together, these experiments confirmed, that 
the insulin signaling and Glut4 levels per se are not affected in young PARP1-/- and 
WT mice, but that the glucose serum levels are already elevated in PARP1-/- mice at 
this age. 
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 DISCUSSION 
Here we show that mice lacking PARP1 have an impaired glucose homeostasis, 
which develops a mature-onset obesity phenotype with insulin resistance which is not 
due to increased caloric intake. Our conclusions are based on several observations: (i) 
body weight and energy expenditure measurements of WT and PARP1-/- on chow or 
high-fat diet, (ii) ITT and GTT measurements of these mice after 13 weeks of diet, 
and, finally (iii) gene expression profiling in liver and adipose tissue of these mice. 
Interestingly, young PARP1-/- mice preserve insulin signaling, strongly indicating 
that the insulin resistance observed in older mice is a consequence of obesity, rather 
than the cause of the observed phenotype.  
 Obesity is a multifactorial disorder and inter- and intrapopulation genetic 
variations exist in susceptibility to diet-induced obesity among various inbred strains 
of mice [33]. Both mono- and polygenic variations contribute to the development of 
obesity phenotype in mice. Spontaneous mutations or variations in the expression 
levels of selective genes can induce obesity when fed a high fat (HF) diet, but little or 
no effect on a low-fat diet [34]. Some inbred strains of mice vary in their 
susceptibility to diet-induced obesity indicating that obesity is a complex trait and 
modifications of multiple genes may be necessary for its etiology [34, 35]. C57Bl/6 
mice were described to be readily susceptible to diet-induced obesity and associated 
type-2 diabetes, while the 129 mouse strain is shown to be resistant to diet-induced 
obesity and insulin resistance [35-37].  
 Insulin resistance is the inability of the peripheral tissues to respond properly 
to insulin. During insulin resistance, this process is blunted, and the persistence of 
hepatic glucose output following a meal compounds diminished glucose uptake into 
muscle, resulting in postprandial hyperglycemia [38]. The observed GTT and ITT 
data strongly indicate at an insulin resistance at the periphery, rather than a 
pathophysiological process in the pancreas.  
Central insulin sensitivity is recognized as of high relevance for hepatic 
glucose metabolism controlled by insulin. Currently we cannot exclude that the 
potential genotypic differences in the brain of WT and PARP1-/- mice might 
contribute the development of T2D in PARP1-/- mice. 
 A mechanism connecting adipose tissue to insulin resistance is the increased 
release of free fatty acids into the circulation that in turn may induce insulin resistance 
in the muscle and possibly in the liver [39]. Adipose tissue produces several 
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 hormones that regulate energy homeostasis, lipid and glucose metabolism such as 
leptin, adiponectin, TNFα and others [40, 41]. Disturbances in the production of these 
factors may contribute to the development of insulin resistance or impaired insulin 
secretion in patients with type 2 diabetes. Type 2 diabetes mellitus with insulin 
resistance is accompanied by abnormal accumulation of triglyceride in the liver, high 
serum triglycerides and low HDL cholesterol [42, 43]. Interestingly the FFA and 
triglyceride levels in WT and PARP1-/- mice were not significantly altered indicating 
that the metabolic disorder was mainly affecting the glucose metabolism in the liver. 
The comparable levels for FFA and triglycerides in both genotypes, might be a 
consequence of increased CD36 levels in PARP1-/- cells. Interestingly, total 
cholesterol levels were increased in PARP1-/- ApoE-/- compared with 
PARP1+/+ApoE-/- mice [44]. The elevated levels were however not considered to be 
relevant for atherogenesis as PARP1-/- ApoE-/- mice exhibited less atherosclerosis 
[44]. 
 White adipose tissue (WAT) has been recognized as an important endocrine 
organ secreting different hormone-like factors (adipokines) and cytokines, thereby 
regulating metabolism locally and systemically [45]. In obesity, excess adipose tissue 
accumulation is accompanied by local inflammation, characterized by infiltration of 
inflammatory cells [46] and by elevated production of proinflammatory cytokines, 
jointly activating inflammatory pathways in adipocytes. It is proposed that the 
consequent alteration in the composition of secreted products from adipocytes 
contributes to both local and systemic insulin resistance [47][48]. Particularly, liver 
insulin sensitivity can be impaired by obesity-induced alterations in adipokine 
secretion and by elevation in fat tissue–derived cytokines. Messenger RNA (mRNA) 
expression of proinflammatory cytokines including IL-6, TNFα, and IL-1 increases 
with increasing adiposity [49, 50]. While it is clear that obesity can induce 
inflammation in adipose tissue, it is possible that inflammation occurs in liver as well 
[51, 52]. Interestingly, we observed the increased expression of proinflammatory 
cytokines in WAT of PARP1-/- cells on ND, which was comparable to these mice on 
HFD. The increased cytokine expression very likely contributes to the insulin 
resistance observed in the liver of these mice. 
NAD+ is a potent activator and substrate of PARP1. Liver NAD+ levels were 
increased by 33% by fasting and returned to control levels after refeeding [62]. These 
data suggest that increased NAD+ concentration might contribute to the PARP1 
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 activity under certain conditions. However NAD+ levels were  comparable in the 
tissues (e.g pancreas and spleen) isolated from WT and PARP1-/- mice suggesting 
that  NAD+ levels are rather unlikely to be the cause for T2D in PARP1-/- mice 
(personal communication). 
 Hepatic glucose production is tightly controlled in vivo. Upon binding of 
insulin to its receptor, tyrosine phosphorylation of IRS1 and 2 results in the 
recruitment of phosphatidylinositol-3-kinase (PI3K), which phosphorylates 
phosphatidylinositol biphosphate into phosphatidylinositol triphosphate (PIP3) [53-
57]. PIP3 recruits to the membrane and activates the serine/threonine kinases PKD1 
and PKB/Akt. The activation of this pathway mediates glycogen synthesis, via 
PKB/Akt inhibitory phosphorylation of glycogen synthase kinase 3 (GSK3), a kinase 
that negatively regulates glycogen synthase. It inhibits, via PKB/Akt-activation of 
Forkhead transcription factors, the transcription of key enzymes for gluconeogenesis: 
phosphoenolpyruvate carboxy-kinase (PEPCK) and glucose-6-phosphatase (G6P). 
Thus through activation of PI3K and PKB/Akt, and subsequent inactivation of GSK3 
and activation of Forkhead transcription factors, insulin promotes storage of glucose 
as glycogen and inhibits glucose synthesis and glucose output.  
 The Forkhead box A2 transcription factor (Foxa2/HNF-3β) has been shown to 
be a key regulator of genes involved in the maintenance of glucose and lipid 
homeostasis in the liver [58]. It is constitutively inactivated in several 
hyperinsulinemic/obese mouse models, thereby enhancing their metabolic 
phenotypes. Foxa2 is activated under fasting conditions but is inhibited by insulin 
signaling via phosphatidylinositol 3-kinase/AKT in a phosphorylation-dependent 
manner, which results in its nuclear exclusion. The negative regulation of Forkhead 
transcription factors by nutritional or stress signals is not unique to Foxa2. In 
mammals, this regulation has also been described for Forkhead transcription Foxo1, 2 
and 3 [59]. Recently, evidence was provided that PARP1 functions as a negative 
regulator of Foxo1 [60]. PARP1 interacts with and poly(ADP-ribosyl)ates Foxo1 
protein. PARP1 represses Foxo1-mediated expression of cell cycle inhibitor p27Kip1 
gene in an enzymatic independent manner. Furthermore, knockdown of PARP1 led to 
a decrease in cell proliferation in a manner dependent on Foxo1 function. Chromatin 
immunoprecipitation experiments confirmed that PARP-1 is recruited to the p27Kip1 
gene promoter through a binding to Foxo1. These results suggest that PARP1 acts as a 
corepressor for Foxo1, which could play an important role in proper cell proliferation 
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 by regulating p27Kip1 gene expression. Whether other Foxo1 target genes involved 
in metabolism are affected by PARP1 is currently not known. Genome-wide analyses 
of genes expressed in liver of PARP1-/- mice revealed the number of down-regulated 
genes was higher than that of the up-regulated genes [23]. The genes with altered 
expression in the livers were also ascribed to the metabolism. Recent transcriptomics 
studies related to type 2 diabetes mellitus have revealed changes in expression of a 
large number of metabolic genes in a variety of tissues. Interestingly, NAD+ was also 
among the novel metabolites that they identified to change with altered glucose 
homeostasis. An algorithm based on the analysis of the promoter regions of the genes 
associated with reporter metabolites revealed a transcription factor regulatory network 
connecting several parts of metabolism. The identified transcription factors include 
members of the CREB, NRF1 and PPAR family, among others, and represent 
regulatory targets for further experimental analysis [61]. 
 Taken together, the presented work sheds new light on the transcriptional 
control of gene involved in gluconeogenesis by PARP1.   
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 Experimental Procedures 
 
Animals and Animal Care 
Wild type or PARP1-/- male C57BL/6 mice were fed a high fat diet consisting of 60% 
of calories from fat (S3282 Bioserv) starting at 6-8 weeks of age for 14weeks. Control 
mice were fed a standard diet consisting of 4.5% fat. Animals were housed in a 
specific pathogen-free facility with a 12-hour light/12-hour dark cycle and given free 
access to food and water. Animal experiments were performed according to the 
regulations of the Cantonal Veterinary Office (Zurich, Switzerland). 
 
Serum Measurements 
Serum insulin concentrations were measured by insulin ELISA kit (Mercodia Inc.). 
Blood glucose was measured by FreeStyle Lite glucometer (Abbott). Leptin 
concentration was measured by Milliplex Mouse Adipokine kit purchased from 
Millipore.  
 
Glucose and Insulin Tolerance Tests 
For glucose tolerance test, mice were fasted overnight (14 hours); glucose (2g/kg 
body weight) was injected intraperitoneally. For the insulin tolerance test mice were 
fasted for 3 hours. and then received human recombinant insulin (0.75U/kg, 1.2U/kg 
or 1.4U/kg body weight) intraperitoneally. Blood glucose concentrations were 
determined from tail using FreeStyle Lite glucometer (Abbott). 
 
Insulin Signaling Analysis 
Muscle, liver and WAT tissues were collected from mice in the basal state or 10 min 
or 20 min after an IP injection of insulin (0.75U/BW), and quickly frozen in liquid 
nitrogen. Frozen tissues were homogenized on ice in RIPA lysis buffer, grinded and 
rocked for 1 hr in cold room. 40 µg proteins were resolved by a 10% SDS-
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes and 
analyzed by immunoblotting.  
 
RNA Extraction and Real-time PCR Analysis 
Mouse tissues were isolated, rinsed in Phosphate Buffered Saline (PBS), frozen in 
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 liquid nitrogen and stored at –80° C until extraction. Total RNA was extracted from 
WAT using the RNeasy Lipid Tissue Kit (Qiagen) according to the manufacturer’s 
instructions with the inclusion of a DNase digestion step. Total RNA from liver and 
muscle was extracted using the ‘Total RNA isolation mini kit’ (Macherey Nagel) with 
a DNase step. Equal amount of RNA from 5-8 mice were pooled and reverse-
transcribed using the ‘High-capacity cDNA reverse transcription kit’ (Applied 
Biosystems). Real-time PCR was performed using the Rotor-Gene 3000 (Corbett Life 
Science, now Qiagen) and SYBR Green using the primers listed in table S1. 
Sequences of all primers were taken from [63]. Cyclophilin was chosen as the internal 
control for normalization after screening several candidate genes. Mean value ± SD 
from two technical replicates was calculated and blotted into graphs with GraphPad 
Prism (GraphPad Software Inc., San Diego, CA, USA). For qPCR with tissue 
samples, WT fed with ND was set as 1. 
 
Indirect Calorimetry 
For the assessment of energy expenditure (EE) and respiratory quotient (RQ), WT and 
PARP1-/- mice, fed either chow or high-fat diet (HF) were individually housed in 
plexiglas air-tight cages designed for open circuit calorimetry (AccuScan Inc., 
Columbus, OH, USA). Group sizes were: WT/chow (n=7), WT/HF (n=9), KO/chow 
(n=6), KO/HF (n=8). Using Integra ME 2.21 software (AccuScan, Inc.), oxygen and 
carbon dioxide levels in each chamber were measured for 30 seconds every 5 
minutes. Based on these values, EE and RQ were calculated according to [64], and 
used to determine average hourly and light- and dark-phase EE and RQ. Data were 
collected for three 23-hour periods. Data from each animal was averaged over the 
three days to calculate representative values for each mouse used for statistical 
analysis. Two animals that lost significant amounts of body weight (more than 10% of 
initial weight) in the metabolic chambers were not included in the analysis.     
All data are represented as mean ± SEM. Statistical significance of differences in EE 
and RQ measurements were tested using two-way ANOVA and Bonferroni’s post-
hoc test for individual comparisons. A p-value < 0.5 was considered statistically 
significant. The software in use was Prism Version 5.0a for Mac OS X (GraphPad 
Software Inc., San Diego, CA, USA). 
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 FIGURE LEGENDS 
 
Fig. 1. PARP1-/- Mice Develop Mature-Onset Obesity 
(A) Body weight measured for WT and PARP1-/-  mice fed with chow or HF diet 
during 14 weeks-period (n=7-9 in each group; t=0, mice 6-8 weeks old). (B) 
Representative images of mice from WT and PARP1-/-  mice fed with chow or high 
fat (HF) diet. (C) Blood glucose levels of 12-14 weeks old mice were measured after 
14 hr fasting. WT (black bar) and KO (white bar) mice fed with chow or HF diet as 
indicated. n = 7-9 mice per group. 
 
Fig. 2. PARP1-/- Mice Display Increased Weight Gain and Decreased Energy 
Expenditure nn Chow Diet 
(A) Leptin levels in serum from WT and PARP1-/-   (KO) mice fed with chow or HF 
diet as indicated. n=7-9 mice per group. *, p-value<0.05. (B) Food intake was 
measured every day for 3 days for WT and PARP1-/-   (KO) mice fed with chow or 
HF diet. n = 7-9 mice. (C) Energy expenditure was measured for three days as 
indicated. 23-hr Energy expenditure (left) and dark- and light-phase energy 
expenditure (middle,right) are shown. Energy expenditure was averaged over the light 
and dark phases and assessed using two-way ANOVA (factors: genotype x diet). 
Bonferroni’s test detected an individual difference between WT and PARP1-/-  (KO) 
in 23-hr Energy expenditure analysis (t= 3.49; *, p-value<0.05). (D) Respiratory 
quotient (RQ) measured for three days as indicated. 23-hr Respiratory quotient (left) 
and dark- and light-phase respiratory  quotient (middle, right) are shown. Respiratory  
quotient was averaged over the light and dark phases and assessed using two-way 
ANOVA (factors: genotype x diet). No significant main effect of genotype on RQ for 
chow- or HF-fed mice (p = 0.46 and 0.62, respectively). 
 
Fig. 3. PARP1-/-  Mice Display Deteriorated Glucose Homeostasis 
(A) Glucose tolerance test (GTT) measured after14 hr-fasting WT and PARP1-/-   
mice fed with chow (left panel) or HFD (right panel). Mice on chow diet were 
injected 2g glucose per body weight (BW), mice on HFD were injected 1.2g glucose 
per body weight. n = 7-9 mice per group, mean ±SE. (B) Serum insulin levels 
measured for mice during GTT shown in (A) at time points 0, 15 and 30 after 
injection. . n = 7-9 mice per group, mean ±SE. (C) Insulin tolerance test (ITT) 
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 measured after 3 hr fasting WT and PARP1-/-  mice fed with chow or HFD. Mice on 
chow diet were injected 1.2 U insulin per body weight, mice on HFD were injected 
1.4U insulin per body weight n = 7-9 mice per group, mean ±SE. (D) Fed serum FFA 
and triglyceride levels from WT (black bar) and KO (white bar) mice fed with ND or 
HFD as indicated. n = 4-5 mice per group, mean ±SE. 
 
Fig. 4. Obesity-Induced Inflammation Is Enhanced in PARP1-/-  Mice on Chow  
(A)  qPCR analysis of expression of genes encoding IL-6, IP-10, MCP-1, TNF-α in 
WAT of WT (black bar) and KO (white bar) mice fed with chow or HFD as indicated. 
n = 5-6 mice, mean ±SD. (B) qPCR analysis of expression of the indicated genes in 
WAT of WT (black bar) and KO (white bar) mice fed with chow or HFD as indicated. 
n = 5-6 mice, mean ±SD.  
 
Fig. 5. Insulin Regulated Gene Expression Is Affected in Liver 
(A) Liver weight normalized with body weight was measured from WT and PARP1-/-  
mice fed with chow or HF diet as indicated. n = 6-8 for each group. (B) Immunoblot 
analysis from the liver extracts of WT and PARP1-/-  mice fed with chow diet (c) or 
with HFD. 2 mice per group. (C-E) qPCR analysis of expression of the indicated 
genes in the liver of WT (black bar) and KO (white bar) mice fed with chow or HFD 
as indicated. n = 5-6 mice, mean ±SD. 
 
Fig. 6. Young PARP1-/-  Mice Preserve Insulin Signaling 
(A) Glucose tolerance test (GTT) measured after 14 hr-fasting of 6 weeks old WT and 
KO mice fed with chow. Mice were IP-injected 2g glucose per BW. n = 5 mice per 
group, mean ±SE. (B) Insulin tolerance test (ITT) measured after 3 hr fasting of 9 
weeks old WT and KO mice fed with chow. Mice were IP-injected with 0.75U insulin 
per BW. n = 5 mice per group, mean ±SE. (C-E) Mice fasted for 14 hr were IP-
injected with 0.75U insulin per body weight. Lysates from muscle (C) liver (D) WAT 
(E) of WT or KO mice fed with chow were immunoblotted with indicated antibodies. 
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Summary  
 
NF-κB regulates the expression of a large number of target genes involved in the 
immune and inflammatory response, apoptosis, cell proliferation, differentiation and 
survival. In this study, we identified SIRT2 as a novel deacetylase of p65. SIRT2 is a 
member of the family of sirtuins, which are NAD+-dependent deacetylases involved 
in several cellular processes. SIRT2 interacts with p65 in the cytoplasm and 
deacetylates p65 in vitro and in vivo at lysine 310. Moreover, p65 is hyperacetylated 
at lysine 310 in Sirt2(-/-) cells after TNFα stimulation, which results in the increase in 
expression of a subset of p65 acetylation-dependent target genes. Together, our work 
provides evidence that p65 is deacetylated by SIRT2 in the cytoplasm to regulate the 
expression of specific NF-κB-dependent genes. 
 
Keywords: NF-κB/ SIRT2/ acetylation/ p65/RelA/K310 
Short title: Deacetylation of RelA by SIRT2 
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Introduction 
Nuclear factor kappa B (NF-κB) belongs to a family of inducible transcription factors 
that modulates gene expression in response to a variety of extracellular and 
intracellular stimuli (Bonizzi et al., 2004; Hoffmann and Baltimore, 2006; Perkins, 
2006). NF-κB plays a crucial role in the regulation of many genes involved in 
mammalian immune and inflammatory response, such as cytokines, cell adhesion 
molecules, complement factors, and a variety of immune receptors. It has additionally 
been implicated as an important regulator of cellular processes such as apoptosis, cell 
proliferation and differentiation. The mammalian NF-κB family includes five 
members, p65 (RelA), c-Rel, RelB, p105/p50 (NF-κB1) and p100/p52 (NF-κB2), 
encoded by RELA, REL, RELB, NFKB1 and NFKB2, respectively (Hayden and 
Ghosh, 2008). These proteins form homo- or heterodimers. The most abundant 
heterodimer in the majority of cells consists of the two subunits p65 and p50. 
 In most unstimulated cells, NF-κB is sequestered in the cytoplasm as an 
inactive transcription factor complex through physical association with one of the 
inhibitors of NF-κB (IκB, predominantly IκBα). NF-κB induction involves the rapid 
activation of IKKβ- and NEMO-dependent phosphorylation and subsequent 
degradation of IκBs. Consequently, dissociation of IκBs from NF-κB unmasks the 
nuclear localization sequence (NLS) of p65, which leads to nuclear translocation and 
binding of NF-κB to specific κB consensus sequences in the chromatin, to regulate 
specific subsets of genes (Ghosh et al., 1998; Pahl, 1999). Interestingly, one 
consequence of NF-κB activation is the upregulation of IκBα gene expression, 
mediated by a κB consensus sequence within the IκBα promoter (Perez et al., 1995). 
Several lines of evidence suggest that newly synthesized IκBα enters the nucleus, 
displaces non-chromatin associated subunits of NF-κB, thereby mediating their export 
from the nucleus and re-establishing a cytoplasmic pool of inhibited complexes 
(Huang et al., 2000). Relocation of NF-κB into the cytoplasm and attenuation of NF-
κB-mediated transcriptional activation therefore provides a feedback mechanism for 
modulating the extent and duration of inflammatory responses by cells. Nevertheless, 
if cells are continuously exposed to a specific stimulus, NF-κB translocates back to 
the nucleus after some time of the first wave of NF-κB induction to continue with 
transcriptional regulation of target genes (Hoffmann et al., 2002). The duration of the 
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NF-κB response depends at least in part on the stimulus applied and on the type of 
analyzed cell.  
 NF-κB specificity is regulated at different levels in the cell (Perkins et al., 
1997). It is plausible that different stimuli induce distinct posttranslational 
modifications of p65, determining the outcome of p65-mediated transcriptional 
events. Several posttranslational modifications on p65 have been described, the most 
important ones being phosphorylation and acetylation (Perkins, 2006). 
Phosphorylation of p65 enhances its interaction with its transcriptional coactivator 
CBP/p300 and with components of the general transcription machinery (Zhong et al., 
2002). Acetylation of p65 was reported to modulate its DNA-binding capacity, its 
transcriptional activity, its interaction with IκB proteins and its subcellular 
localization (Chen et al., 2001; Kiernan et al., 2003). We recently showed that p65 is 
acetylated by p300 not only at lysine 310 (K310), but also at K314 and 315, two 
novel acetylation sites, and that acetylation of K314 is important for late gene 
expression (Buerki et al., 2008; Rothgiesser et al., 2010). Microarray analysis of 
genetically complemented p65 knockout (-/-) cells treated with tumor necrosis factor 
α (TNFα) identified specific sets of genes differentially regulated by acetylation 
deficient mutants of p65 compared to wild type cells. Together, these results showed 
that site-specific p300-mediated acetylation of p65 regulate the specificity of NF-κB-
dependent gene expression.  
 Reversible protein acetylation is an important posttranslational modification 
that regulates the function of histones and many other proteins (Sterner and Berger, 
2000). Acetylation has a rapid turnover due to the highly dynamic equilibrium 
between two different groups of enzymes, histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). The balance between these two activities is key to 
regulate the appropriate cellular response to signals. Mammalian HDACs are divided 
into four main classes based on sequence similarity and cofactor dependency (Class I-
IV) (Yang and Seto, 2007). Class III HDACs, also known as sirtuins, constitute a 
special class of enzymes because of their requirement for NAD+ as a cofactor in their 
deacetylation reaction. During the deacetylation reaction, nicotinamide (Nam) is 
cleaved from NAD+ and the acetyl group of the substrate is then transferred to ADP 
ribose, generating the novel metabolite 2’-O-acetyl-ADP ribose (OAADPr) (Denu, 
102
  
2003). The sirtuin family consists of seven members in mammals (SIRT1–7) that 
contain a conserved catalytic core domain comprised of approximately 275 amino 
acids. They regulate a variety of cellular functions, such as genome maintenance, 
longevity, and metabolism (Oberdoerffer and Sinclair, 2007; Westphal et al., 2007; 
Yamamoto et al., 2007). Up to date, all sirtuins have been described to have 
deacetylation activity except for SIRT4 (Taylor et al., 2008). The SIRTs exhibit 
differential localization from nucleus to nucleolus, and from cytoplasm to 
mitochondria (Sauve et al., 2006).  
SIRT2 is the counterpart of yeast Hst2p, both proteins localize to the 
cytoplasm (Perrod et al., 2001). SIRT2 was found to bind HDAC6 and to deacetylate 
α-tubulin, thereby participating in the regulation of microtubule dynamics and 
possibly cell cycle progression (Dryden et al., 2003; North et al., 2003; Pandithage et 
al., 2008). Presumably, SIRT2 regulates other cellular functions, as p53, p300 and 
histones (H3 and H4) have been identified as substrates (Black et al., 2008; Heltweg 
et al., 2006; Vaquero et al., 2006). The apparent contradiction of a protein being 
cytoplasmically located, yet exhibiting specificity for a histone residue was resolved 
when SIRT2 localization was monitored during cell cycle progression. SIRT2 
localized to the cytoplasm throughout the cell cycle with the exception of prophase 
during G2/M transition, where it translocated to the nucleus to deacetylate histone H4 
at lysine 16 (H4K16) (Vaquero et al., 2006). Moreover, MEFs derived from Sirt2(-/-) 
mice showed hyperacetylation of H4K16 during mitosis (Vaquero et al., 2006). In 
addition, the dynamic analysis of the subcellular localization of SIRT2 revealed that 
this enzyme shuttles continuously between the cytoplasmic and nuclear compartments 
during interphase (North and Verdin, 2007).  
Based on our recent findings, we extended our studies to further elucidate the 
molecular regulation of p65 acetylation. Here, we describe the characterization of 
SIRT2 as a novel deacetylase of p65. Furthermore, gene expression analysis in 
SIRT2-deficient MEFs indicate that SIRT2-mediated p65 deacetylation is implicated 
in transcriptional regulation of a subset of genes. 
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Results 
Generation and verification of a specific antibody against acetylated p65 K310. 
To further assess the functional relevance of p65 acetylation in vivo, we generated 
different antibodies raised against the acetylated K310. The selected antibody 
recognized specifically p65 acetylated in vitro and in cells by p300 at K310 (Fig. 1A 
and B). Furthermore, we investigated the kinetics of p65 acetylation in response to 
TNFα stimulation in cells. p65(-/-) MEFs stably complemented with p65 were 
stimulated for the indicated times (20 to 90 minutes). Western blot analysis of 
immunoprecipitated p65 from the nuclear fraction of the cells revealed that 
endogenous p65 predominantly translocated after 20 minutes of TNFα treatment into 
nucleus which correlated with its acetylation at K310 (Fig. 1C). The signal 
dramatically decreased after 45 minutes of stimulation and was no longer detectable 
after 90 minutes, which correlates with the reported cytoplasmic relocalization of p65 
in MEFs after TNFα stimulation (Hoffmann et al., 2002). Together, these experiments 
revealed that p65 is acetylated at K310 in a TNFα-dependent manner, possibly upon 
translocation to the nucleus. 
 
p65 is deacetylated by SIRT1 and SIRT2 at K310 in vitro. 
The reversed acetylation of p65 prompted us to investigate which enzyme might be 
responsible for p65 deacetylation at K310. Here we focused on sirtuins. To elucidate 
which sirtuin can deacetylate p65 at K310, we purified (baculovirus expressed) 
recombinant SIRT1, 2, 6 and 7 that are known to localize either to the nucleus or to 
the cytoplasm (Fig. 2A). Recombinant purified p65 was acetylated in vitro by p300 
and subsequently incubated with purified recombinant SIRT1, 2, 6 and 7, in the 
presence or absence of NAD+. While SIRT2 was able to deacetylate p65 completely 
already after 30 minutes, as observed by western blot analysis using the anti-acK310 
anbibody, SIRT1 was only able to do so after extended incubation (Fig. 2B and S1A). 
SIRT6 and 7 were not able to deacetylate p65 under the tested conditions.  
 
p65 is deacetylated by SIRT2 at K310 in vivo. 
Since SIRT1 has been previously reported to deacetylate p65 (Yeung et al., 2004), we 
decided to focus on SIRT2. To confirm that SIRT2 is able to deacetylate p65 also in 
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vivo, his-tagged SIRT2 and 6 or 7 (as negative controls) were overexpressed in HEK 
293T cells (Fig. S1B), along with myc-tagged p65. Stimulation of transfected cells 
with TNFα for 30 minutes resulted in effective acetylation of p65 K310 (Fig. 2C, 
mock sample). Notably, overexpression of SIRT2 significantly reduced p65 
acetylation at K310, while SIRT6 and SIRT7 were not able to deacetylate p65 under 
these conditions (Fig. 2C). Similarly overexpressing of class I HDACs HDAC1, 2 and 
3 was insufficient to deacetylate K310 of p65 (Fig. S1C and D). To verify that the 
deacetylase activity of SIRT2 was necessary for p65 deacetylation, we overexpressed 
wt and a catalytically inactive mutant of SIRT2 (H187Y) together with p65 in HEK 
293T cells (Fig. 2D). The enzymatic inactive SIRT2 mutant was, as expected, unable 
to deacetylate p65 at K310. These findings indicate that SIRT2 is capable to 
deacetylate K310 of p65 in cells. 
 
TNFα  stimulation does not induce nuclear translocation of SIRT2. 
Next, we decided to investigate if SIRT2 translocates to the nucleus upon TNFα 
stimulation. Since endogenous SIRT2 could not be detected by immunofluorescence, 
we overexpressed HA-tagged SIRT2 in HeLa cells and stimulated the cells with 
TNFα for 30 or 90 minutes. Immunofluorescence studies revealed that overexpressed 
SIRT2 and endogenous p65 localized to the cytoplasm in untreated cells (Fig. 3A). 
After 30 minutes of TNFα stimulation, p65 translocated to the nucleus and relocated 
to the cytoplasm after 90 minutes, while SIRT2 stayed in the cytoplasm throughout 
the experiment, indicating that SIRT2 does not shuttle to the nucleus upon TNFα 
stimulation (Fig. 3A).  
 
SIRT2 forms a complex with p65 in the cytoplasm, which is enhanced by TNFα  
stimulation. 
To investigate whether endogenous SIRT2 and p65 would interact in vivo, p65 was 
immunoprecipitated from cytoplasmic or nuclear extracts of THP1 cells. Interestingly, 
SIRT2 coimmunoprecipitated with p65 in the cytoplasmic extracts under basal 
conditions, indicating that p65 forms a complex with SIRT2 in untreated cells (Fig. 
3B). While TNFα stimulation induced p65 nuclear translocation, enhanced 
p65/SIRT2 complex formation was observed in the cytoplasmic fraction (Fig. 3B). 
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SIRT2 did not immunoprecipitate with nuclear p65, confirming that TNFα did not 
induce SIRT2 translocation. 
 
SIRT2 deacetylates p65 at K310 in the cytoplasm.  
To provide further evidence for the cytoplasm as the cellular compartment where 
SIRT2 deacetylates p65, HEK 293T cells were transfected with expression plasmids 
for different SIRT2 mutants containing an additional NLS or an NLS in combination 
with a NES deletion (NLSΔNES). While wild type SIRT2 was located exclusively in 
the cytoplasm, fusion of an NLS to SIRT2 slightly increased its nuclear localization 
(Fig. 3C). Complete nuclear localization of SIRT2 could be observed only upon 
additional deletion of the NES (NLSΔNES mutant). Importantly, analysis of the p65 
acetylation status under these conditions revealed that the nuclear localization of 
SIRT2 negatively correlated with p65 deacetylation (Fig. 3D). The mutation of SIRT2 
to achieve nuclear localization (SIRT2 NLSΔNES mutant) did not abolish its 
deacetylation activity, since it was able to efficiently deacetylate H4K16 in the 
nucleus (Fig. S2A and B). Collectively, these results suggest that SIRT2 interacts with 
and deacetylates p65 exclusively in the cytoplasm. 
 
Hyperacetylation of p65 at K310 in Sirt2(-/-) cells. 
To further investigate the role of SIRT2 in p65 deacetylation in vivo, Sirt2(-/-) and 
Sirt2(+/+) MEFs were stimulated with TNFα and acetylation of endogenous p65 was 
analyzed by western blot. The increase in acetylation of endogenous p65 at K310 
upon TNFα stimulation was substantially larger in Sirt2(-/-) as compared to wild type 
MEFs (Fig. 4A). Protein levels of SIRT1 were not altered in the analyzed MEFs (Fig. 
4B). Moreover, Sirt1(-/-) MEFs did not display hyperacetlyted p65 (Fig. S2A). 
Together, these results provide strong evidence that SIRT2 is the predominant enzyme 
involved in deacetylation of p65 at K310 after TNFα stimulation in vivo.  
 
SIRT2 regulates NF-κB-dependent gene expression. 
Since p65 acetylation influences NF-κB-dependent transcription, we decided to 
investigate whether depletion of SIRT2 affects the expression of NF-κB target genes 
upon TNFα stimulation in vivo. We analyzed the expression of Mpa2l, a gene 
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previously identified as NF-κB-dependent (Rothgiesser et al., 2010), that requires 
acetylation of p65 at K310 for its transcriptional activation (Fig. S2B). Gene 
expression analysis by real-time RT-PCR in Sirt2(+/+) and Sirt2(-/-) MEFs uncovered 
a dramatic increase in Mpa2l expression in Sirt2(-/-) cells compared to Sirt2(+/+) 
cells in response to TNFα (70 fold difference, Fig. 4C). The same was not observed 
for the control RELA, a gene that has neither been reported to be dependent on NF-κB 
nor to be a housekeeping gene (www.nf-kb.org) (Fig.4D). Moreover, knockdown of 
p65 in Sirt2(-/-) cells reduced the induction of Mpa2l expression (Fig. S2C and D). 
Furthermore, transient knockdown of Sirt2 with siRNA in MEFs enhanced Mpa2l 
expression as well, although not to the same extent (Fig. S2E and F). This correlated 
with our results showing that acetylation of p65 at K310 is required for transcriptional 
activation of Mpa2l (Fig. S2B) and that p65 is hyperacetylated in Sirt2(-/-) MEFs 
(Fig. 4A). Furthermore, these data imply that the expression of genes that are 
particularly dependent on K310 acetylation are strongly induced in Sirt2(-/-) cells, as 
observed for the strong Mpa2l induction in vivo.  
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Discussion 
We have previously shown that p65 acetylation plays an important role in regulating 
NF-κB-dependent transcription for a subset of target genes. Here we report the 
identification of SIRT2 as a novel p65 deacetylase. SIRT2 deacetylates p65 in vitro 
and when overexpressed in cells after TNFα stimulation. Furthermore, endogenous 
p65 and SIRT2 interact in the cytoplasm of unstimulated cells. Subsequent TNFα 
treatment does not trigger SIRT2 translocation to the nucleus, but enhances complex 
formation with p65 after 30 to 60 minutes, thus indicating that it deacetylates p65 in 
the cytoplasm. Moreover, p65 is hyperacetylated at K310 in Sirt2(-/-) MEFs, which 
correlates with a strong increase in Mpa2l expression, a gene which is dependent on 
the acetylation of p65 at K310. 
We observed that p65 was rapidly acetylated at K310 in the nucleus of MEFs 
upon TNFα stimulation and that the signal was drastically reduced after 45 minutes of 
TNFα treatment (Fig. 1C). Immunostaining and EMSA experiments have previously 
shown that the majority of NF-κB shuttles back to the cytoplasm between 30 to 60 
minutes after TNFα stimulation in MEFs (Buerki et al., 2008; Hoffmann et al., 
2002). Strikingly, the timing of p65 deacetylation at K310 correlates with its reported 
export to the cytoplasm, supporting the idea that p65 is deacetylated in the cytoplasm.  
HDAC3 and SIRT1 have been previously described to deacetylate p65 (Chen 
et al., 2001; Yeung et al., 2004). However, we did not detect p65 deacetylation by 
overexpressed HDAC3 in HEK 293T cells. This discrepancy might be due to different 
experimental procedures, such as the use of HEK 293T cells instead of COS-7 cells. 
Deacetylation of K310 by SIRT1 was shown in vitro with recombinant proteins and in 
HEK 293T cells with overexpressed proteins, which correlates with our results but 
particularly the latter may be the consequence of overexpressing the proteins. 
Hyperacetylation of K310 upon TNFα stimulation in the Sirt2, but not Sirt1(-/-) 
MEFs suggests that SIRT2, but not SIRT1, is critical to deacetylate K310 of p65 in 
cells. Our experiments with Sirt1(-/-) cells are in agreement with observations where 
RNAi of SIRT1 did not lead to changes in NF-κB target gene expression, unless cells 
were treated with resveratrol (Yeung et al., 2004). These results suggest that SIRT1 
and SIRT2 might function independently in p65 deacetylation and does not exclude 
that SIRT1 is relevant for the deacetylation of other lysines in p65. Recently, a study 
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showed that SIRT6 does not deacetylate p65 in vitro or in vivo, in agreement with our 
results (Fig. 2B and C), but deacetylates histone H3K9 to attenuate NF-κB signaling 
(Kawahara et al., 2009).  
 Gene expression analysis of Sirt2(-/-) MEFs revealed that transcriptional 
activation of Mpa2l, whose expression was dependent on p65 acetylation at K310 
(Fig. S2A), was dramatically increased in Sirt2(-/-) cells compared to another gene, 
RELA, whose expression does not depend on K310 acetylation (Fig. 4D). Therefore, 
we propose that SIRT2 regulates the expression of a subset of NF-κB-dependent 
genes by deacetylating p65 at K310 in the cytoplasm upon relocation of NF-κB to this 
cellular compartment after the first wave of NF-κB induction. Since NF-κB is known 
to shuttle between nucleus and cytoplasm in 30-60 minutes periods in MEFs upon 
continuous TNFα stimulation (Hoffmann et al., 2002), p65 would be hyperacetylated 
in Sirt2(-/-) cells after 3 hours of TNFα treatment, which would explain the observed 
differential Mpa2l gene regulation.  
Despite the identification of p65 acetylation, the exact mechanism by which 
p65 K310 acetylation regulates the expression remains to be further elucidated. Huang 
et al. reported that double bromodomain of Brd4 binds to acetylated K310, which 
enhances transcriptional activation of NF-κB and the expression of a subset of NF-κB 
inflammatory genes in an acetylated K310-dependent manner (Huang et al., 2008).  
Our data suggest that in unstimulated cells, SIRT2 exists in a complex with 
p65. Upon TNFα stimulation, p65 translocates to the nucleus, while SIRT2 stays in 
the cytoplasm. Co-activator p300 binds to nuclear p65 and acetylates it at K310, 314 
and 315 to fine tune gene expression. Once the NF-κB response is terminated, p65 
shuttles back to the cytoplasm, where SIRT2 deacetylates p65 at K310, thereby 
resetting the whole NF-κB response. Any p65 that would afterwards translocate to the 
nucleus again during continuous TNFα stimulation would have to be freshly 
acetylated by p300 to modulate gene expression, thereby allowing a tight control of 
NF-κB-dependent transcription. 
Together, our results identify SIRT2 as a novel deacetylase of NF-κB and an 
important regulator of TNFα-induced NF-κB-dependent gene expression. 
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Materials and methods 
Tissue culture 
Complemented p65(-/-) NIH 3T3 mouse embryonic fibroblasts (MEFs) stably 
expressing p65 wild type or the acetylation-deficient mutants were previously 
described in (Buerki et al., 2008). They were maintained in DMEM supplemented 
with 10% FCS, 100 units/ml penicillin/streptomycin (Gibco) and non-essential amino 
acids (Gibco). Sirt2(-/-) and (+/+) MEFs were a generous gift from A. Vaquero. 
Those cells were originally generated in the lab of F. Alt (Vaquero et al., 2006). 
Sirt1(-/-) and (+/+) MEFs were kindly provided by F. Alt (Cheng et al., 2003). Sirt1(-
/-) , Sirt1(+/+), Sirt2(-/-) and Sirt2(+/+) MEFs were kept in DMEM supplemented 
with 15% FCS, 100 units/ml penicillin/streptomycin (Gibco), non-essential amino 
acids (Gibco), β-mercaptoethanol (Gibco) and Na-Pyruvate (Gibco). HEK 293T and 
HeLa cells were maintained in DMEM supplemented with 10% FCS and 100 units/ml 
penicillin/streptomycin. THP1 cells were maintained in RPMI medium containing 
10% FCS, 100 units/ml penicillin/streptomycin (Gibco), non-essential amino acids 
(Gibco), β-mercaptoethanol (Gibco) and Na-Pyruvate (Gibco).  
  
Plasmids  
Plasmids for the mammalian expression of human p65 wild type and mutants K310R, 
K314/315R and KTR were described elsewhere (Buerki et al., 2008). Mammalian 
expression plasmids of human SIRT1, 2, 6 and 7 in the pcDNA-DEST40-V5/HIS 
background were kindly provided by I. Horikama (Michishita et al., 2005). The 
enzymatic inactive mutant was generated by site-directed mutagenesis of H187 to Y 
with pcDNA-DEST40-SIRT2 as template. The introduced mutation was verified by 
DNA sequencing. Plasmids for the expression of HA-tagged SIRT2 and HA vector 
control were described elsewhere (Pandithage et al., 2008). The GW-pHA-SIRT2-
NLS vector was created by cloning the sequence 5’-
GATCCCCAAAGAAGAAGCGAAAGGTAC into GW-pHA-SIRT2. Site-directed 
mutagenesis was performed to change the SIRT2 K4 and K12 to alanines, creating the 
GW-pHA-SIRT2-NLSΔNES vector. The introduced sequence and mutations were 
verified by DNA sequencing. 
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Reagents and antibodies 
Human tumor necrosis alpha (TNFα), Trichostatin A (TSA), Nicotinamide (Nam) and 
acetyl-Coenzyme A (acetyl Co-A) were purchased from Sigma. Recombinant mouse 
TNFα was either purchased from Sigma or generated in our laboratory. Sodium 
fluorid (NaF) and beta-glycerophosphate were obtained from Fluka. The acetyl-
specific antibodies for p65 anti-acetyl K310 (ab19870) was generated by Abcam. The 
following antibodies were purchased from Santa Cruz Biotechnologies: anti-p65 (sc-
372), anti-p300 (sc-585) and anti-SIRT2 (sc-20966 and sc-28298). The anti-SIRT1 
antibody was from Millipore (07-131). The anti-myc antibodies were either purchased 
from Roche (11-667-149-001) or purified from hybridoma cells. The anti-tubulin 
antibody was purchased from Sigma (T 6199), the anti-his was from Qiagen (34670) 
and the anti-HA was from Covance (MMS-101P). 
 
Generation of recombinant proteins  
The recombinant proteins were expressed by baculovirus in Sf21 cells using either the 
FastBac or the BacPAK systems (Clontech). His-tagged proteins were purified over 
Ni2+-beads (ProBond, Invitrogen) and GST-tagged proteins over L-Glutathione beads 
(Sigma).  
 
In vitro acetylation assay 
1 µg of recombinant p65 wild type or the acetylation-deficient mutants were 
incubated with 500 ng recombinant p300 in HAT buffer (50 mM Tris HCl pH8, 100 
mM NaCl, 10% glycerol, 1mM PMSF, 1mM DTT, 1 µg/ml bepstatin, 1 µg/ml 
leupeptin, 1 µg/ml pepstatin and 1 mM sodium butyrate) with or without addition of 
150 µM acetyl-CoA. After 1 hour at 30°C, samples were resolved on SDS-PAGE and 
analyzed by western blot. 
 
In vitro deacetylation assay 
500 ng recombinant p65 wild type was in vitro acetylated as described previously and 
then immunoprecipitated. The beads-bound p65 was incubated with 14 pmol of each 
recombinant SIRT in 100 µl deacetylation buffer (50 mM Tris HCl pH9, 4 mM 
MgCl2, 0.2 mM DTT, 1 µg/ml bepstatin, 1 µg/ml leupeptin and 1 µg/ml pepstatin) 
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supplemented or not with 1 mM NAD+ for 30 minutes or 2 hours with constant 
agitation. Proteins were subsequently resolved in SDS-PAGE and analyzed by 
western blot. Purified recombinant SIRTs were additionally resolved on SDS-PAGE 
and stained with coomassie blue. 
 
Acetylation and deacetylation assays in cells 
HEK 293T cells were transfected with expression plasmids for p300 and either myc-
tagged p65 wild type, the acetylation-deficient mutants or an empty vector, using the 
calcium phosphate precipitation method. After 23 hours, cells were treated with 10 
ng/ml human TNFα for 30 minutes. Then, whole cell extracts were prepared and 40 
µg protein was analyzed by SDS-PAGE and western blot. For the deacetylation assay 
in cells, 0.1 pmol expression plasmid encoding the different sirtuins (wild type or 
mutants) or empty vector were additionally co-transfected in HEK 293T cells. 
 
Immunostaining 
Transfected HEK 293T cells or HeLa cells were stimulated with 10 ng/ml human 
TNFα for 30 minutes. They were fixed with 4% paraformaldehyde and then 
permeabilized with 0.2% TritonX-100. Blocking solution (2% BSA and 0.1% 
TritonX-100 in PBS) was added for 1 hour before the slides were incubated with anti-
HA and anti-p65 antibodies (1:250 each in blocking solution), followed by incubation 
with FITC-labeled anti-mouse and Cy3-labeled anti-rabbit antibodies (1:250 each in 
blocking solution, Jackson Immunology). The slides were washed, covered with 
Vectashield mounting solution (Vector laboratories) and visualized using a Leica SP 5 
confocal microscope. 
 
Nuclear and cytoplasmic extract preparation and immunoprecipitation   
THP1 cells were stimulated with 10 ng/ml TNFα for the indicated time periods, 
harvested, washed once with PBS, and washed three times in buffer A (10 mM 
HEPES KOH pH7.9, 1.5mM MgCl2, 10 mM KCl, 1µg/ml pepstatin, 1µg/ml bestatin, 
1µg/ml leupeptin, 2mM PMSF, 5mM DTT). Cells were lysed with A+ buffer (Buffer 
A+ 0.05 % NP-40) and centrifuged for 5 minutes at 5000 rpm. Supernatant 
corresponding to cytoplasm was saved and kept on ice till the nuclear fraction was 
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ready. Pellet was washed three times with buffer A and subsequently resuspended in 
three volumes of Buffer C (20 mM HEPES KOH pH7.9, 0.42 M NaCl 1.5 mM 
MgCl2, 25% v/v glycerol, 1µg/ml pepstatin, 1µg/ml bestatin, 1µg/ml leupeptin, 2 mM 
PMSF, 5 mM DTT) and incubated for 15`at 4°C on rotating wheels. Lysate was 
centrifuged for 10 minutes at 4°C at 14000 rpm and the supernatant corresponding to 
nuclear extract was seperated for immunoprecipitation.150 µg nuclear extracts or 450 
µg cytoplasmic extracts were mixed with IP buffer (20mM HEPES KOH pH 7.9, 
2.5mM MgCl2, 0.1/ NP-40, 50mM NaCl, 1µg/ml pepstatin, 1µg/ml bestatin, 1µg/ml 
leupeptin, 2mM PMSF) in a final of 120mM NaCl concentration, 2.5 % of the mix 
was saved for the input analysis. p65 antibody was added and incubated for 2 hours at 
4°C on a roller. At the end of the incubation, prewashed protein G beads were added 
to the mix for another 2 hours. Finally, beads were washed three times with IP buffer 
containing 120 mM NaCl. Beads and the inputs were added Laemmli buffer, boiled 
and resolved on SDS-PAGE and subjected to western blot using different antibodies. 
 
Gene expression by real-time RT-PCR 
Complemented MEFs were starved overnight before treatment with 30 ng/ml 
recombinant TNFα for different time points. Sirt2(+/+) and Sirt2(-/-) MEFs were 
starved for 6 hours and then stimulated with 30 ng/ml recombinant TNFα for 3 hours 
or left unstimulated. Total RNA was isolated from at least two biological samples at 
different days with the ‘Total RNA isolation mini kit’ (Agilent Technologies). RNA 
was subsequently retro-transcribed using the ‘High-capacity cDNA reverse 
transcription kit’ (Applied Biosystems). Real-time PCR was performed using the 
Rotor-Gene 3000 (Corbett Life Science, now Qiagen) and TaqMan assays from 
Applied Biosystems for Mpa2l, Mmp13, Rps6 and CanX genes. The last two genes 
were used as internal controls to normalize for RNA input. In addition, gene 
expression of Mpa2l, Mmp13, RELA and Rps12 (as internal control) was assessed 
with SYBR Green using the following primers: Mpa2l_forward 
(GATGCTGAAGAAGCTAATGAAGG ATC), Mpa2l_reverse 
(CCTTGATGACATCTCTCAGTTGCTG), Mmp13_forward 
(GGACAAGCAGTTCCAAAGGCTACA) and Mmp13_reverse 
(GTCTTCATCGCCTG GACCATAAAG). RNA from at least two biological 
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replicates per sample was measured and analyzed with REST (Pfaffl et al., 2002). 
Each experiment was run three independent times, the mean value and ± SD was 
calculated and blotted into graphs. 
 
Transient Transfections 
MEF cells were seeded on 6-well tissue culture plates and next day transfected with 
30 pmol siRNA oligos (Qiagen) with 4 µl Lipofectamine RNAimax reagent 
(Invitrogen) according to manufacturer`s protocol for two days.  
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Figure legends 
 
Figure 1. Kinetics of p65 K310 acetylation upon TNFα  stimulation. (A-B) 
Characterization of specific antibody against p65 acetylated at K310. (A) Purified 
recombinant p65 wild type and the acetylation-deficient mutants were incubated with 
recombinant p300 in the presence (+) or absence (-) of acetyl CoA. Proteins were 
resolved on SDS-PAGE and analyzed by western blot using the indicated antibodies. 
(B) HEK 293T cells were transfected with p65 wild type or mutants, with (+) or 
without (-) p300 co-transfection. Acetylation of p65 at specific K310 was assessed by 
western blot using the specific antibody. (C) Endogenous p65 is rapidly and possibly 
transiently acetylated in the nucleus upon TNFα stimulation in vivo. Wild type 
complemented MEFs were treated with TNFα for the indicated time periods. p65 was 
immunoprecipitated from nuclear extracts and analyzed by western blot using anti-
acetyl K310 antibody. PARP1 from 5% input was used as nuclear loading control. 
 
Figure 2. SIRT2 deacetylates p65 at K310.  
(A) Expression and purification of hist-tagged SIRT1, SIRT2, SIRT6 or SIRT7 from 
insect cells. (B) In vitro acetylated p65 wild type was incubated for 30 minutes with 
recombinant sirtuins in the presence (+) or absence (-) of NAD+. Deacetylation was 
confirmed by Western blot analysis using the acK310 specific antibody. (C) 
Overexpressed SIRT2 deacetylate p65 in HEK 293T cells. HEK 293T cells were 
transfected with the expression plasmids for the indicated his-tagged SIRTs along 
with p300 and myc-tagged p65. Whole cell extracts were prepared after 30 minutes of 
TNFα stimulation and analysed by western blot. (D) Deacetylase activity of SIRT2 is 
required for p65 deacetylation in cells. SIRT2 wild type or the enzymatic inactive 
mutant was overexpressed in HEK 293T cells together with p300 and myc-tagged 
p65. The acetylation status of p65 after 30 minutes of TNFα stimulation was assessed 
with the indicated antibody.  
 
Figure 3. SIRT2 deacetylates p65 in the cytoplasm.  
(A) p65 translocates to the nucleus in response to TNFα stimulation, while SIRT2 
stays in the cytoplasm. HeLa cells were transfected with HA-tagged SIRT2 and 
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stimulated with TNFα for the indicated time points, followed by immunofluorescence 
detection of p65 and HA-SIRT2. Dapi staining shows the nucleus. Subcellular 
localization of p65 and HA-SIRT2 was analysed with a confocal microscope. (B) p65 
interacts with SIRT2 in the cytoplasm. THP1 cells were stimulated with TNFα for the 
indicated time points. p65 was immunoprecipitated from nuclear and cytoplasmic 
extracts and analyzed by western blot using indicated antibodies. Levels of PARP1 as 
nuclear control are shown. (C) HEK 293T cells were transfected with HA-tagged 
SIRT2 wild type, NLS mutant or NLSΔNES mutant. After 30 minutes of TNFα 
stimulation, cells were fixed and immunostained with anti-HA antibody to display 
cellular localization of SIRT2 wild type and mutant proteins, assessed with a confocal 
microscope. (D) Strongly reduced decatylation of p65 acK310 upon overexpression of 
nuclear SIRT2 mutant. The same constructs as in (C) were overexpressed in HEK 
293T cells along with p65 wild type and p300, followed by 30 minutes of TNFα 
stimulation, whole cell extracts preparation and western blot analysis with the 
indicated antibodies.   
 
Figure 4. Lack of SIRT2 increases TNFα-induced NF-κB-dependent 
transcriptional activation.  
(A) Endogenous p65 is hyperacetylated in Sirt2(-/-) cells. MEFs from the indicated 
genotypes were pre-treated with the HDAC inhibitors (HDACi) TSA and Nam for 30 
minutes and then stimulated with TNFα for 1 hour before preparing whole cell 
extracts. Extracts were analyzed by western blot using anti-acK310 antibody. The 
membrane was reprobed for p65, and tubulin was used as loading control. * indicates 
a non-specific band. (B) Western blot analyses for endogenous SIRT1 and SIRT2 in 
Sirt2(-/-) cells. Tubulin was used as loading control. Gene induction of Mpa2l (C) and 
RELA (D) in Sirt2(+/+) and Sirt2(-/-) MEFs after 3 hours of TNFα stimulation, as 
measured by real-time RT-PCR. At least two biological replicates were analyzed. 
Shown are the means ± SD of three independent runs.  
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Figure S1.  
(A) In vitro acetylated p65 wild type was incubated for 120 minutes with recombinant 
sirtuins in the presence (+) or absence (-) of NAD+. Deacetylation was confirmed by 
Western blot analysis using the anti-acK310 specific antibody. (B) HEK 293T cells 
were transfected with the expression plasmids for the indicated his-tagged SIRTs. 
Whole cell extracts were prepared after 30 minutes of TNFα stimulation and analysed 
by western blot. (C) HEK 293T cells were transfected with the expression plasmids 
for the indicated myc-tagged HDACs. Whole cell extracts were prepared after 30 
minutes of TNFα stimulation and analysed by western blot. (D) The indicated 
HDACs were overexpressed in HEK 293T cells together with p300 and myc-tagged 
p65. The acetylation status of p65 after 30 minutes of TNFα stimulation was assessed 
with the indicated antibody.  
 
Figure S2.  
(A) HeLa, transient transfection, stained as indicated. Pictures were taken with a  
confocal microscope. (B) HeLa cells were transfected with expression vectors 
encoding the indicated proteins. The transfected cells were selected and the 
acetylation of different sites on H4 analyzed by Western blotting. The different 
antibodies were used on parallel blots. 
 
Figure S3. 
(A) Sirt1(+/+) and Sirt1(-/-) MEFs were pre-treated with the HDAC inhibitors 
(HDACi) TSA and Nam for 30 minutes and then stimulated with TNFα  for 1 hour 
before preparing whole cell extracts. Extracts were analyzed by western blot using 
anti-acK310 antibody. The membrane was reprobed for p65, and tubulin was used as 
loading control. * indicates a non-specific band. (B) Gene induction of Mpa2l in p65(-
/-) in a TNFα-dependent manner, as measured by real-time RT-PCR, from the 
following complemented cell lines: wild type (green), K310R (orange) and pTV 
(black). Samples were normalized to Rps6 and CanX expression levels, and expressed 
as fold increase relative to wild type unstimulated. Two biological replicates were 
included. Shown are the means ± SD of three independent runs. (C) TNFα-dependent 
Mpa2l activation is p65-dependent. Knock-down of p65 in Sirt2(-/-) cells. p65 levels 
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were assessed by western blot analysis; and (D) Sirt2(-/-) MEFs were transiently 
transfected with the indicated siRNA oligos and stimulated with TNFα for 3 hours. 
Mpa2l gene induction was measured by real-time RT-PCR. (E) Knock-down of Sirt2 
increases gene induction of NF-κB target genes. (F) p65(-/-) MEFs stably 
complemented with wt p65 were transiently transfected with the indicated siRNA 
oligos, stimulated with TNFα for 3 hours and gene induction of Mpa2l was analyzed 
by real-time RT-PCR. 
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Abstract
Hypoxia-inducible factor 1 (HIF-1) is the key
transcription factor regulating hypoxia-dependent gene
expression. Lack of oxygen stabilizes HIF-1, which in
turn modulates the gene expression pattern to adapt
cells to the hypoxic environment. Activation of HIF-1 is
also detected in most solid tumors and supports tumor
growth through the expression of target genes that are
involved in processes like cell proliferation, energy
metabolism, and oxygen delivery. Poly(ADP-ribose)
polymerase 1 (PARP1) is a chromatin-associated
protein, which was shown to regulate transcription.
Here we report that chronic myelogenous leukemia
cells expressing small interfering RNA against PARP1,
which were injected into wild-type mice expressing
PARP1, showed tumor growth with increased levels
of necrosis, limited vascularization, and reduced
expression of GLUT-1. Of note, PARP1-deficient cells
showed a reduced HIF-1 transcriptional activation that
was dependent on PARP1 enzymatic activity. PARP1
neither influenced binding of HIF-1 to its hypoxic
response element nor changed HIF-1A protein levels
in hypoxic cells. However, PARP1 formed a complex
with HIF-1A through direct protein interaction and
coactivated HIF-1A–dependent gene expression. These
findings provide convincing evidence that wild-type
mice expressing PARP1 cannot compensate for the loss
of PARP1 in tumor cells and strengthen the importance
of the role of PARP1 as a transcriptional coactivator
of HIF-1–dependent gene expression during tumor
progression. (Mol Cancer Res 2008;6(2):282–90)
Introduction
In solid tumors, rapid cell proliferation is associated with
areas of hypoxia. Intratumoral hypoxia induces neoangio-
genesis, which is an essential switch from tumorigenesis to
tumor progression (1). Oxygen limitation regulates vascular-
ization, glucose metabolism, cell survival, and tumor spread.
The hypoxic response critically depends on the transcription
factor hypoxia-inducible factor-1 (HIF-1; ref. 2). HIF-1a was
found to be overexpressed in more than 70% of human
cancers and their metastases (3). The effect of HIF-1 on
tumor growth is complex and involves the activation of
several adaptive pathways and results in the induction of
target genes (4). In solid tumors, immunohistochemistry often
shows larger fronts of HIF nuclear expression delineating
areas of necrosis (5). Induction of HIF is therefore believed
to be supportive, if not causative, in cancer (6-8). In tumor
xenograft and orthotopic mouse models, manipulation of the
levels of either HIF-1a or HIF-2a has shown a causal link
between HIF expression and tumor progression (4). HIF
signaling has emerged as an important hypoxia-driven
response allowing tumor cells to survive, expand, and invade.
As a result, tumor hypoxia or HIF expression is strongly
associated with a diminished therapeutic response and malignant
progression (9).
HIF induction is a multistep process, which is tightly
regulated in vivo (10, 11). HIF-1 is composed of two
polypeptides: HIF-1a and HIF-1h (12). Two additional HIF-a
members, the closely related HIF-2a (13) and more distantly
related HIF-3a (14), were recently identified. HIF-1 activity is
regulated at the posttranscriptional level by protein degradation
of HIF-1a subunits after oxygen-dependent hydroxylation of
specific proline residues (15). During hypoxia, the prolyl
hydroxylases are inactive and HIF-1a is not complexed with
the ubiquitin E3 ligase complex containing von Hippel Lindau,
thereby allowing for the formation of active HIF-1 complexes
(2, 5, 12). Transactivation involves dimerization of the two
HIF-1 subunits, which bind to an enhancer element, called
hypoxia response element, in target genes. Among the most
studied promoters with regard to the recruitment of HIF-1 are
those of the EPO , GLUT-1 , and CA9 [carbonic anhydrase IX
(CAIX)] genes (16-18). The presence of hypoxia response
element sites is necessary, but not sufficient, to direct gene
expression in response to hypoxia, suggesting that HIF-1 must
interact with other transcription factors or cofactors bound
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around these sites (19). The assembly of a higher-order HIF-1
transcription complex is an important stage in HIF-1–
dependent transcription, involving multiple coactivator/cofac-
tor-HIF-1-DNA interactions. Two key coactivators of HIF-1 are
the histone acetyltransferases p300 and its homologue, the
cyclic AMP-responsive element binding protein–binding
protein, which can directly associate with the COOH-terminal
transactivation domain of HIF-1a. HIF-1a also interacts with
other coactivators such as SRC-1 and TIF1 (20).
Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear
chromatin-associated protein and belongs to a large family of
enzymes that can synthesize polymers of ADP-ribose units by
using h-NAD+ as substrate (21). Several studies showed that
PARP1/ mice were protected against myocardial infarction,
streptozotocin-induced diabetes, lipopolysaccharide-induced
septic shock, zymosan-induced vascular failure, a nonseptic
model of multiple organ dysfunction, as well as collagen-
induced arthritis (21). We recently presented evidence that
PARP1 can act as a coactivator of nuclear factor nB
in vivo (22).
In a 12-O-tetradecanoylphorbol-13-acetate– induced skin
cancer model, PARP1 was suggested to be important for tumor
induction (23). The importance and contribution of PARP1 for
tumor progression in tumor cells is still not clear. Here we
present evidence that tumors derived from chronic myeloge-
nous leukemia cell line K562 lacking PARP1 but grown in
wild-type mice expressing PARP1 show a significant increase
in necrotic areas, reduced vascularization, and reduced
expression of GLUT-1 , a HIF-1–dependent gene. HIF-1–
dependent gene expression was also reduced in K562
cells expressing siRNA against PARP1 (siPARP1) or primary
PARP1/ mouse lung fibroblasts (MLF). PARP1 interacted
directly with HIF-1a, providing convincing evidence that
PARP1 acts mechanically as a transcriptional cofactor of
HIF-1a transcriptional activation. Interestingly, HIF-1–depen-
dent gene expression was dependent on the enzymatic activity
of PARP1. Taken together, our results show that PARP1 and its
enzymatic activity are important for tumor progression,
possibly leading to new therapeutic approaches for the
treatment of human tumors.
FIGURE 1. The down-regulation of PARP1 enhances tumor cell death but does not affect tumor growth. Chronic myeloid leukemia cell line K562 was
subcutaneously injected in athymic nude mice. Cells with down-regulated PARP1 gene by transduction of siPARP1 were compared with cells transfected
with siMock. A. Tumor growth curves for siMock (5) and siPARP1 (o) injected mouse groups (four mice and eight implantation sites for each group). Bars,
SE. B. Staining of tumor sections with anti-PARP1 antibody confirmed the sustained down-regulation of PARP1 in tumor cells after subcutaneous growth in
mice. PARP1 staining (red ), nuclear staining [4¶,6-diamidino-2-phenylindole (DAPI; blue )], and merged image (merge ) indicated presence of PARP1 in the
nuclei of wild-type (wt) tumors. C. Representative pictures of tumors stained by H&E indicating an enhanced presence of necrotic tumor areas in siPARP1
tumors. D. Quantification of necrotic lesions. All tumors were sequentially sectioned and areas from three different depths of tumor were H&E stained and
evaluated. Number of necrotic lesions in each tumor type is presented in a group of mice (P < 0.001). E. Staining of tumor sections with anti –glucose-
transporter (GLUT-1) antibody (red ) and 4¶,6-diamidino-2-phenylindole (blue ) reveals down-regulation of GLUT-1 expression in siPARP1 tumors.
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Results
Down-Regulation of PARP1 Induces Areas of Necrosis in
Tumors
To test the role of PARP1 in tumor progression, we stably
transduced cell line K562 with a construct expressing siPARP1
or the corresponding mock control using a scrambled sequence
(siMock). Down-regulation of PARP1 was analyzed by
immunoblot of cell lysates (see Supplementary Fig. S1A).
The established siMock and siPARP1 cells were subcutane-
ously injected in both flanks of athymic nude mice. First signs
of tumor formation appeared as early as 1 week postinjection
for both cell groups. The formation of tumors was obvious
2 weeks after implantation. Tumor growth was similar in
both mouse groups, irrespective of PARP1 down-regulation
(Fig. 1A). To confirm that PARP1 was still down-regulated in
these tumors, we stained the sections with anti-PARP1
antibody (Fig. 1B). Whereas siMock tumors were positive
for PARP1, no signal was visible in siPARP1 tumors.
Histologic evaluation of tumors from siPARP1 cells showed
larger areas of necrosis (areas with no nuclear-blue staining)
compared with their controls (Fig. 1C). Quantification of
necrotic areas revealed that the incidence (number of lesions)
and size of lesions were increased in tumors expressing
siPARP1 (12-22 lesions per tumor in siPARP1 tumors versus
2-9 lesions in siMock tumors; Fig. 1D and data not shown).
The areas of cell death with histologic necrotic features were
further analyzed by detection of glucose transporter GLUT-1,
which is known to be up-regulated in the hypoxic areas of
tumors (24). Whereas siMock tumors showed almost homog-
enous presence of GLUT-1, large areas without GLUT-1
staining were observed in siPARP1 tumors (Fig. 1E).
Immunohistochemical analysis with the endothelial marker
CD31 revealed a significantly decreased blood vessel density
in the siPARP1 tumors (Fig. 2). The reduced vascularization
corresponded well with the increased number of necrotic areas
observed in siPARP1 tumors, indicating limited blood supply.
Repeated experiments with mouse colon carcinoma cell line
MC38 injected in a syngeneic mouse model (C57BL/J6)
provided the same pattern of enhanced necrosis in the absence
of PARP1 (data not shown). These data indicate that the
constitutive down-regulation of PARP1 by siRNA did not
affect tumor growth within the limits allowed by animal
protocol, but caused larger areas of cell death, which in turn
could affect tumor progression. Together with the reduced
levels of GLUT-1 in siPARP1 tumors, those results suggested
the involvement of PARP1 in HIF-dependent gene expression.
HIF-Dependent Gene Expression Is Impaired in
siPARP1-Expressing K562 Cells
To test whether PARP1 influences HIF-dependent gene
expression, siMock- and siPARP1-expressing K562 cells were
treated with ciclopirox olamine (25), a hypoxiamimetic drug,
and the expression of HIF-dependent genes was assessed by
transient transfection of a reporter gene under the control of
hypoxia response element (Fig. 3A). The experiments revealed
that ciclopirox olamine– induced expression levels of the
reporter gene were dependent on HIF and severely reduced in
siPARP1-expressing K562 cells. Transfection of siPARP1-
expressing K562 cells with a nondegradable PARP1 restored
the observed HIF-1–dependent gene expression (Fig. 3A),
confirming that PARP1 is required for HIF-1–dependent gene
expression.
HIF-Dependent Gene Expression Is Impaired in Primary
PARP1/ MLF
To further investigate the contribution of PARP1 in HIF-
dependent gene expression, primary PARP1+/+ and PARP1/
MLF were exposed to different concentrations of ciclopirox
olamine or hypoxia as indicated, and the expression of HIF-
dependent genes was assessed by reporter gene analysis as
described above (Fig. 3B and C). Ciclopirox olamine– induced
expression of the reporter gene was again severely reduced in
PARP1/ cells when compared with wild-type MLF (Fig. 3B).
The experiments under hypoxic conditions (1% O2) confirmed
that PARP1 is important for HIF-1–dependent gene expression
(Fig. 3C).
The Enzymatic Activity of PARP1 Is Required for Full HIF-
Dependent Transcription
To explore whether the enzymatic activity was important for
HIF-dependent gene expression, cells were treated with the
PARP inhibitor DAM-TIQ-A. Efficacy of the inhibitor was
tested in K562 cells treated with H2O2. DAM-TIQ-A was
shown to efficiently suppress the H2O2-induced formation of
poly(ADP-ribose) (Supplementary Fig. S1B). siMock- and
siPARP1-expressing K562 cells were then treated with DAM-
TIQ-A and subsequently incubated under hypoxic conditions
(1% O2). RNA levels of HIF-1 target gene CAIX were
FIGURE 2. Reduced vascularization of K562 tumors is associated with
the down-regulation of PARP1. A. Tumor vasculature was evaluated by
immunohistochemical staining with CD31 antibody. Representative pic-
tures show a higher number of blood vessels in siMock tumors compared
with scarcely vascularized siPARP1 tumors. Bar, 100 Am. B. Vascular
density based on CD31 staining is quantified for both tumors. The
decreased number of blood vessels in siPARP1 tumors was found
statistically significant by Student’s t test (P < 0.01).
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measured by quantitative real-time PCR (Fig. 3D). Inhibition of
PARP1 in siMock cells also resulted in a reduction comparable
to the level obtained by knockdown of PARP1. Treatment of
siPARP1-expressing cells with inhibitor did not further reduce
CAIX expression levels.
Normal HIF-1 Signaling in PARP1-Deficient Cells
To investigate the molecular mechanism of PARP1 regula-
tion of HIF-1–dependent gene expression, we analyzed
whether the activation of the HIF-1 signaling pathway is
overall affected in PARP1-deficient cells on stimulation with
ciclopirox olamine or hypoxia. Immunoblot analysis of nuclear
extracts from siMock- and siPARP1-expressing K562 revealed
that HIF-1a was induced to equal levels after stimulation with
ciclopirox olamine (Fig. 4A). Additionally, these experiments
showed that there is equivalent nuclear stabilization of HIF-1a
in the tested cells. Repeated experiment with PARP1+/+ and
PARP1/ MLF provided the same conclusions (data not
shown). DNA binding activity of HIF-1 on naked templates
was tested by electrophoretic mobility shift assay studies with
MLF extracts and DNA oligonucleotides corresponding to the
hypoxia response element sites of the erythropoietin EPO
promoter. PARP1 deficiency did not influence HIF-1 binding to
the template (Fig. 4B). Addition of an anti–HIF-1a antibody
induced a supershift, confirming that HIF-1 was indeed present
in the observed complex (Fig. 4C).
PARP1 Forms a Complex with HIF-1 and Binds Directly to
HIF-1 In vitro
HIF-1 and p300/cyclic AMP-responsive element binding
protein–binding protein were shown to form a ternary complex
and to function synergistically to enhance the activity of nuclear
receptors (26). Thus, PARP1 might also synergistically
coactivate HIF-1–mediated transactivation. To directly test
whether PARP1 physically interacts with HIF-1, we immuno-
precipitated PARP1 from HeLa whole-cell extracts after
FIGURE 3. PARP1 is required for HIF-1–dependent gene expression. A. Transient reporter assay in cell lines K562 siMock, siPARP1, and siPARP1
complemented with wild-type PARP1. Cells were transfected with either the hypoxia reporter (Epo ) or the mutated control (mut ) and treated with 15 Amol/L
ciclopirox olamine (CPX ) for 10 h. Cells were harvested and hypoxia-dependent gene expression was determined. The depicted fold increase is calculated as
the ratio of normalized luciferase activity of the Epo reporter over the mut reporter. Bars, range of two replicates. B. PARP1+/+ and PARP1/ MLF were
transfected with either the hypoxia reporter or the mutated control and treated with the indicated amount of ciclopirox olamine for 12 h. Cells were harvested
and hypoxia-dependent gene expression was determined. The depicted fold increase is determined by normalization of the relative luciferase activity of the
reporter plasmids to that of an internal control (RSV-hGal). The ratios for untreated mutant reporter in both cell lines were arbitrarily set to 1. Bars, range of
two replicates. C. Cells were prepared as in B but kept in either normoxic (21%) or hypoxic (1%) condition for 9 h after transfection. The depicted fold
increase is calculated as the ratio of normalized luciferase activity of the Epo reporter over the mut reporter. Bars, SD of three replicates. D. Quantitative
reverse transcription-PCR analysis of CAIX expression. siMock- and siPARP1-expressing K562 were treated with DAM-TIQ-A as indicated and incubated in
normoxic (21% O2) or hypoxic (1% O2) conditions. Induction is defined as the ratio of hypoxic over normoxic CAIX levels. The induction of untreated siMock
cells was arbitrarily set to 100%. Bars, SD of four replicates.
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stimulation with ciclopirox olamine and tested for the presence
of HIF-1a by immunoblot analysis. HIF-1a formed a complex
with PARP1 (Fig. 5A), which was not mediated by DNA
because the presence of ethidium bromide did not affect
complex formation (data not shown). To further confirm a
direct protein-protein interaction, we bound recombinant
purified full-length glutathione S-transferase (GST)-PARP1 to
glutathione beads followed by incubation with in vitro
translated HIF-1a subunit, and bound proteins were resolved
by SDS-PAGE. PARP1 bound directly to the HIF-1a subunit
(Fig. 5B). Similar binding was observed for HIF-2a but not for
HIF-3a, HIF-1h, or HIF-2h subunits (Supplementary Fig. S1C
and data not shown).
Expression of PARP1 Increases HIF-1a–Dependent
Transactivation in PARP1/ Cells
To further investigate the functional relevance of the
PARP1-HIF-1a interaction, primary PARP1+/+ and PARP1/
MLF were transfected with an expression plasmid for HIF-1a,
and the expression of HIF-1a–dependent genes was assessed
by reporter gene analysis as described above (Fig. 3).
Transcriptional activation by HIF-1a expression was again
severely reduced in PARP1/ cells when compared with wild-
type MLF (Fig. 5C). The same experiment using a plasmid with
a mutated promoter confirmed that the observed gene
expression is indeed HIF-1a specific. Assuming that the
reduced luciferase levels in PARP1/ MLF (Figs. 3 and 5C)
are indeed due to the absence of PARP1, one expects
that complementation of PARP1/ cells with the wild-type
PARP1 gene restores HIF-1–dependent gene expression. HIF-
dependent reporter plasmids (wild-type and mutant) were
therefore cotransfected in PARP1/ MLF with expression
vectors for HIF-1a and PARP1. Overexpression of PARP1 or
HIF-1a alone could not, or modestly, activate HIF-dependent
gene expression; however, coexpression of HIF-1a with
PARP1 synergistically activated HIF-1a–dependent transcrip-
tional activation (Fig. 5D). In the same set of experiments, we
did not observe transcriptional coactivation of HIF-2a by
PARP1, suggesting that HIF-2a might be regulated differen-
tially by PARP1. The regained ability of PARP1/ MLF to
activate genes in a HIF-1a–dependent manner on reintroduc-
tion of PARP1 provides convincing functional evidence that
PARP1 acts as a classic transcriptional coactivator of HIF-1–
dependent gene expression.
Discussion
HIF-1– regulated genes have been implicated in the
promotion of tumor progression and metastasis by enhancing
angiogenesis, cell proliferation, and the resistance to apoptotic
cell death (27). In this study, we find that PARP1 is a regulator
of HIF-1–dependent xenograft tumor progression. Mechanis-
tically, we identified PARP1 as a transcriptional coactivator of
HIF-1– induced gene expression and we determined a novel
process of HIF-1 regulation under hypoxia that acts through
PARP1 by regulating target gene expression of critical HIF-1
genes such as GLUT-1, CAIX, EPO , and VEGF.
The knockout strategy has revealed an important role of
PARP1 in cell death after myocardial or brain ischemia-
reperfusion injury (28, 29). Significant protection against
oxidant-induced tissue damage can also be achieved with
FIGURE 4. HIF-1 stabilization and DNA binding activity are not affected in PARP1/ cells. A. K562 siMock and siPARP1 cell lines were treated with
15 Amol/L ciclopirox olamine for 14 h. Nuclear proteins were then extracted and resolved by SDS-PAGE followed by immunoblot analysis with anti-PARP1
and anti –HIF-1a antibodies. Anti-tubulin was used as a loading control. B. Autoradiographs of electrophoretic mobility shift assay for 32P-labeled
oligonucleotides containing a HIF-1 binding site. Nuclear extracts of PARP1+/+ and PARP1/ MLF treated with 10 Amol/L ciclopirox olamine for 6 h were
used in the assay. Competition for binding was done with unlabeled wild-type and binding mutant oligonucleotides. C. Confirmation of HIF-1 binding was
effected by adding anti –HIF-1a (HIF ) or control IgG (c ) antibodies for a supershift.
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pharmacologic PARP1 inhibitors (30). The most obvious
explanation for this observation is that on reperfusion,
oxygen-derived free radicals, NO, and peroxynitrite induce
DNA breaks, which in turn overactivate PARP1 (31). This
excessive activation leads to intracellular NAD and ATP
depletion resulting in mitochondrial free radical generation
and necrosis (32, 33). Whether these observed effects are due to
anoxia or reduced nutritional supply or both (e.g., ischemia) is
currently not clear. In our tumor model, we found PARP1 to
promote cell survival rather than cell death. The observed
increase in necrotic areas in tumors grown from PARP1-
deficient cells was also accompanied by a decrease in
vascularization of tumors. These findings are in agreement
with earlier observation that inhibition of PARP1 decreases
angiogenesis in an in vitro model (34). We therefore propose
that insufficient oxygen and nutrient supply due to impaired
HIF-1 activation is the cause for the increased necrosis during
tumor progression, independent of radical oxygen species
formation. Experiments by Tong et al. (35) provided evidence
that in a p53/ background, PARP1 is important as cofactor
for suppression of tumorigenesis in certain tissues. Conde
et al. (36) reported that injection of ras-transformed PARP1/
p53/ cells failed to generate any visible tumor. We did not
observe an influence of PARP1 protein on tumor latency and
cell proliferation using K562 or MC38 cells (data not shown).
This could be due to the fact that both cell lines are expressing
functional p53. Furthermore, our results indicate that in a p53-
proficient background, PARP1 acts as promoter of tumor
survival as shown by the increase of necrosis in tumors formed
by siPARP1-expressing K562 and MC38 cells. Obviously, the
tissue expressing PARP1 around the tumors was not able to
overcome the lack of PARP1 in the tumor cells.
Our gene expression studies suggest a transcriptional
coactivator role for PARP1 in HIF-1–dependent gene
expression because in the absence of PARP1, impaired
expression of HIF-1–dependent genes was found when mouse
fibroblasts and K562 cells were exposed to ciclopirox olamine
or hypoxia. Interestingly, the protein levels of HIF-1 were not
reduced in treated cells, indicating that the signaling pathway
and turnover rate of HIF-1 per se were not affected. Moreover,
the DNA binding activity of HIF-1 assayed in vitro on naked
nonchromatinized templates was not impaired in nuclear
extracts from PARP1/ fibroblasts, suggesting that HIF-1
does not require PARP1 for binding to its hypoxia response
element.
Complementation experiments of PARP1/ cells with a
PARP1 expression plasmid confirmed that PARP1 is required
when HIF-dependent gene expression is activated by HIF-1a
overexpression. We detected endogenous PARP1 in a complex
with HIF-1. Moreover, PARP1 directly bound to the HIF-1a
subunit in vitro. Together these observations implicate that
PARP1 is playing a critical and central role downstream of the
HIF signaling pathway and strengthens the involvement of
PARP1 as transcriptional coactivator. It is of great interest to
elucidate the relationship of PARP1 to other HIF-1–associated
coactivators with regard to their relative contribution to
HIF-1–dependent gene activation, in relation to different
promoters and stimuli. Chromatin immunoprecipitation experi-
ments could be used to study the presence of PARP1 at pro-
moters of HIF-1–dependent genes. Unfortunately, such
experiments are made difficult by the lack of suitable
antibodies and the high affinity of PARP1 for DNA strand
breaks in general.
FIGURE 5. PARP1 directly interacts with HIF-1a and synergistically
activates HIF-1a–dependent gene expression. A. Immunoprecipitation of
HIF-1a with anti-PARP1 antibody serum (a-P1) and preimmune serum
(pre ) as a control. Total extracts of HeLa cells treated with 15 Amol/L
ciclopirox olamine for 16 h were used. Input lane (inp ) was loaded with
10% the amount of extract used for the immunoprecipitation. The sizes of
protein marker bands (M ) are indicated in kilodaltons. B. Autoradiography
of in vitro translated HIF-1a pulled down with GST-PARP1 (P1 ) or GST
alone (GST ). Input lane was loaded with 1% the amount of translation
product used for the pull-down. C and D. PARP1/MLF were transfected
for 24 h by polyethylenimine with either the hypoxia reporter or the mutated
control together with PARP1 or HIF-1a, as indicated. Cells were harvested
and hypoxia-dependent gene expression was determined. The depicted
fold increase is determined by normalization of the relative luciferase
activity of the reporter plasmids to the protein concentration of each
sample. The ratios for untreated mutant reporter in both cell lines were
arbitrarily set to 1. Bars, SD of three replicates.
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The requirement of PARP1 enzymatic activity for HIF-1–
dependent transcription is shown by experiments including
PARP inhibitors. As such, expression of CAIX was reduced in
the presence of the PARP inhibitor DAM-TIQ-A. Thus, for at
least a subset of PARP1-dependent HIF-1 target genes, the
enzymatic activity of PARP1 is necessary for full activation.
Whether only PARP1 is poly(ADP-ribosylated) or also other
factors, such as histones or even HIF-1a, has to be further
elucidated. Two groups recently reported that lack of
homologous recombination by BRCA1 and BRCA2 dysfunc-
tion sensitized tumor cells to the inhibition of PARP enzymatic
activity (37, 38). Others provided evidence that the enzymatic
activity of PARP1 can also be induced by D-myo-inositol-
1,4,5-triphosphate in a DNA damage–independent mechanism
(39). Whether the observed effect of PARP inhibitor is due to
the PARP1 activation induced by damaged DNA or other
stimuli has to be further investigated. PARP inhibitors were
also reported to possess free radical scavenging properties
(40). Because hypoxia could potentially induce local oxidative
stress, it is tempting to speculate that PARP inhibitors with
antioxidative potency contribute indirectly and nonspecifically
to decreased HIF-1–dependent transcriptional activity by
reduction of free radicals. We cannot exclude that the observed
effects are due to the off-targeting activity of PARP inhibitors
(41, 42). The residual activation of gene expression in the
presence of PARP inhibitor might be explained by a process
that is independent from PARP1. The small observed
difference between siRNA knockdown and pharmacologic
inhibition, on the other hand, could be due to incomplete
knockdown of PARP1 or the contribution of other PARP
family members.
Martin-Oliva et al. recently provided evidence that the
number of 7,12-dimethylbenz(a)anthracene– and 12-O-tetra-
decanoylphorbol-13-acetate– induced skin tumors is reduced in
mice treated with PARP inhibitor, suggesting that PARP1 is
important for tumor initiation. They suggested that the
transcriptional activity of HIF-1 was compromised by PARP
inhibition or, in immortalized PARP1-deficient cells, on
stimulation with 12-O-tetradecanoylphorbol-13-acetate or des-
feroxamine (an iron chelator and activator of HIF; ref. 23). In
contrast, our studies provide evidence that PARP1 is important
for the progression of tumors formed by transformed cell lines
and that wild-type mice expressing PARP1 cannot compensate
for the loss of PARP1 in cancer cells. One possible explanation
for the observed discrepancies is the differences in examined
tumor types. Furthermore, our studies with primary PARP1/
MLF and siPARP1-expressing cells under hypoxic conditions
or treated with a hypoxiamimetic drug revealed that HIF-1
signaling (HIF-1 protein stability and DNA binding) per se is
not affected by PARP1.
By integrating our data with previous findings, we propose a
model by which HIF-1 regulation under hypoxic conditions
occurs additionally through PARP1 as transcriptional coactiva-
tor. The presence of PARP1 stimulates HIF-1–dependent gene
expression and thus allows induction of genes involved in
neoangiogenesis and cell survival. From a therapeutic point of
view, inhibition of PARP1 enzymatic activity could be an
effective target in conditions of tissue ischemia because tumors
lacking PARP1 show increased necrosis on ischemic insult.
Thus, well-tolerated PARP1 inhibitors that are known to inhibit
PARP1 enzymatic activity (38) could be beneficial in the
treatment of HIF-1–dependent tumor progression.
Materials and Methods
Reagents and Antibodies
Ciclopirox olamine was purchased from Sigma and
dissolved in methanol before diluting to final concentration in
supplemented media. Radiochemicals were obtained from
Amersham Biosciences. The anti-PARP1 antibody is described
in ref. 43, and the anti–HIF-1a antibody in ref. 44. Antimouse
IgG was purchased from Santa Cruz Biotechnology. Anti–
GLUT-1 antibody was purchased from Abcam, Inc. Anti-PAR
antibody was a kind gift of Guy Poirier.
Mouse Strains and Experiments
All animal procedures were done in accordance with the
regulations of the Cantonal Veterinary Authority of Zurich in
accordance with the Swiss laws on animal protection.
For the tumor growth studies, athymic nude mice (HsdCpb:
NMRI-Foxn1nu) were obtained from Harlan Laboratories.
Eight-week-old females were injected subcutaneously with
8  106 K562 chronic myelogenous leukemia cells, which were
either stably transfected with siRNA against PARP1 (siPARP1
tumors) or transfected with mock siRNA (siMock tumors).
Tumor growth was checked regularly and mice were terminated
when the size of tumor was reaching approved limits.
Histology
Dissected tumors were macroscopically evaluated, cut in
half, and frozen in embedding medium (Tissue-Tek O.C.T.
compound, Sakura, USA, Inc.). Paraformaldehyde-fixed cry-
osections (8 Am) were blocked in 0.5% bovine serum albumin
and incubated with either polyclonal rabbit anti-PARP1 or
rabbit anti-GLUT-1 (Abcam) antibody for 1 h at room
temperature. Tumors were further incubated with Cy3-conju-
gated goat anti-rabbit antibodies (Jackson ImmunoResearch)
followed by nuclear staining with 4¶,6-diamidino-2-phenyl-
indole and mounting in Prolong medium (Invitrogen). Forma-
lin-fixed cryosections were stained with H&E and evaluated for
the presence of necrosis. The quantification of necrosis was
done on the whole area of each tumor in several sections. Blood
vessels were stained with CD31 antibody (Becton Dickinson).
Specific binding was detected with the Vectrastain ABC Kit
with the AEC substrate (Vector Laboratories) followed by
hematoxylin counterstaining.
Generation of siRNA Cell Lines
Generation of viruses and transduction of cells were pre-
viously described (45). After several rounds of selection, expres-
sion level of PARP1 was screened by immunoblot analysis.
Cell Culture, Transient Transfection, and Nuclear Extracts
Mouse PARP1+/+ or PARP1/ MLF cells were isolated
from 129S/EV-PARP1+/+ and 129S/EV-PARP1/ mice, both
described in ref. 46. Only cell passages 2 to 10 were used for
experiments. MLF and HeLa cell lines were grown in DMEM
Glutamax-I (Invitrogen) containing 4.5 g/L glucose. K562 cells
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were grown in RPMI (Invitrogen). All media were supple-
mented with 10% FCS (Invitrogen), 50 units/mL penicillin,
50 Ag/mL streptomycin (Sigma), and a-naphthylacetic acid
(Invitrogen). Cells were grown in 5% CO2 at 37jC in a
humidified incubator. MLF and HeLa cells were transfected
with polyethylenimine or calcium phosphate, and K562 cells
with DEAE-dextran, as previously described. Because of
differences in transfection efficiencies, an expression plasmid
of h-galactosidase (pph-RSV-nt-h-gal; ref. 47) was cotrans-
fected as a transfection efficiency control, and luciferase
activities were normalized based on h-galactosidase activity.
In case of K562 and MLF, normalization was done with total
protein amount measured by Bradford assay. Luciferase activity
was measured as described in ref. 48. Nuclear extracts of HeLa
and K562 cells were produced as described in ref. 49.
Quantitative Real-time PCR
Total RNA of cells was extracted with the RNA Isolation
Mini Kit (Agilent) following the manufacturer’s protocol. RNA
was then reverse transcribed with the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Quantitative
PCR was done on a Rotor-Gene 3000 machine (Corbett
Research) with TaqMan probes (Applied Biosystems) against
two endogenous controls (ribosomal proteins P0 and S14) and
against CAIX. Quantitation was done using the Rotor-Gene
software version 6.1 (Corbett Research) and the built-in two-
standard curve method.
Plasmids
The reporter plasmid p5xHREwt was created by cloning one
oligonucleotide containing a HIF-1 binding site from the VEGF
promoter (5¶-AGCTTGATATCGGATCCGCATACGTGGGCT-
CCAACAGGTCCTCTTCCCTCCCAGTCACTGAC-
TAACCCT-3¶; binding site underlined) and two oligonucleo-
tides containing two binding sites from the EPO promoter
(5¶-AGCTTGGATCCGGCCCTACGTGCTGCCTCGCATGG-
GCCCTACGTGCTGCCTCGCATGGCCC-3¶; binding sites
underlined) into the multiple cloning site of pGL3-Basic
(Promega). For p5xHREmut, the oligonucleotides were the
same except for the binding sites that were changed to
5¶-TAAAAGGG-3¶ and 5¶-TAAAAGCT-3¶, respectively. Ex-
pression vectors CMV-HIF-1a, CMV-HIF-2a, and CMV-
HIF-3a used for in vitro transcription were constructed by
PCR amplification of the open reading frame of I.M.A.G.E.
cDNA clones #3842146, #6305604, and #6250259, respectively.
PCR products were then ligated into pphCMV-T7-km-3
described in ref. 50.
shRNA coding sequences (available on request) were cloned
into pSUPER vector by using BglII and HindIII cloning sites.
BamHI/SalI fragment containing HI promoter upstream of
shRNA coding sequence was subcloned into pRDI292 vector
(51). The envelope plasmid pMD.G and the packaging plasmid
pCMV-DR8.91 have previously been described (45).
In vitro Transcription/Translation and GST Pull-Down
Assays
GST and GST-PARP1 were expressed in Escherichia coli.
In vitro transcription/translation reactions were carried out with
the TNT T7 Quick Coupled Transcription/Translation System
(Promega) according to the manufacturer’s protocol. GST pull-
down assays were done with bacterial extracts, glutathione-
Sepharose beads (Amersham Pharmacia Biotech), and the
radiolabeled product in the presence of 80 mmol/L NaCl as
described in ref. 52.
Immunoprecipitation and Immunoblot
For immunoprecipitation, 1 mg of HeLa nuclear extract was
incubated with anti-PARP1 serum or preimmune serum in
immunoprecipitation buffer containing 80 mmol/L NaCl and
Protein A-Sepharose beads (Amersham Biosciences). Beads
were then extensively washed in the presence of 100 mmol/L
NaCl and 0.05% NP40, followed by SDS-PAGE and immuno-
blot analysis according to the manufacturer’s protocol (enhanced
chemiluminescence; Pierce).
Electrophoretic Mobility Shift Assay
The electrophoretic mobility shift assay was done as
described in ref. 53. Briefly, the oligonucleotides 5¶-GCCCT-
ACGTGCTGCCT-3¶ and 5¶-GCCCTAAAAGCTGCCT-3¶ were
annealed to their antisense counterparts, labeled with 32P by T4
PNK, and purified in Microspin G-25 columns (Amersham
Biosciences). The radiolabeled oligonucleotides were then
added to 10 Ag of HeLa nuclear extract. After 20 min, samples
were loaded and separated on a 4% native acrylamide gel. The
gels were then dried for autoradiography. For competition,
HeLa nuclear extracts were preincubated for 5 min with
unlabeled competitor oligonucleotides for a final ratio of 25:1
of unlabeled over labeled oligonucleotide. For supershift,
nuclear extracts were preincubated for 20 min with anti–
HIF-1a or with an unrelated antimouse IgG antibody.
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